Document:

EX-10.1

 Exhibit 10.1 
 SECOND AMENDED AND RESTATED| 
 INVESTORS’ RIGHTS AGREEMENT

 THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is
made and entered into as of December 28, 2012, by and among ARATANA THERAPEUTICS, INC., a Delaware corporation (the “Company”), and the investors set forth on the Schedule of Investors attached hereto as
Exhibit A (each, an “Investor” and collectively, the “Investors”). 

RECITALS 

WHEREAS, the Company and certain of the Investors (the “Existing Investors”) are parties to that certain
Series A Preferred Stock Purchase Agreement (the “Series A Purchase Agreement”) or that certain Series A-1 Preferred Stock Purchase Agreement (the “Series A-1 Purchase Agreement”
and, together with the Series A Purchase Agreement, the “Prior Purchase Agreements”), each dated as of December 27, 2010; and 
 WHEREAS, as a condition of entering into the Prior Purchase Agreements, the Existing Investors and the Company executed that certain Investors’ Rights Agreement dated as of December 27,
2010 among the Company and such Investors (the “Prior Agreement”); and 
 WHEREAS, the Company
and certain of the Investors (the “Series B Investors”) are parties to that certain Series B Preferred Stock Purchase Agreement dated as of November 1, 2011, among the Company and the Series B Investors
(the “Series B Purchase Agreement”); and 
 WHEREAS, as a condition of entering into the
Series B Purchase Agreement, the Series B Investors, the Existing Investors and the Company executed that certain First Amended and Restated Investors’ Rights Agreement dated as of November 1, 2011 (the “Restated Prior
Agreement”). 
 WHEREAS, certain of the Investors (the “Series C Investors”)
are parties to that certain Series C Preferred Stock Purchase Agreement of even date herewith among the Company and the Series C Investors (the “Series C Purchase Agreement”); and 

WHEREAS, as a condition of entering into the Series C Purchase Agreement, the Series C Investors have requested that the
Company and Existing Investors and Series B Investors representing at least the Majority Investors amend and restate the Restated Prior Agreement as set forth below. 
 NOW, THEREFORE, in consideration of the foregoing recitals and the mutual promises, representations, warranties, and covenants hereinafter set forth and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Existing Investors and the Series B Investors hereby agree that the Restated Prior Agreement shall be amended and restated, and the parties to this Agreement further agree as
follows: 

 AGREEMENT 

 

	1.	REGISTRATION RIGHTS. 

1.1 Definitions. For purposes of this Agreement: 
 (a) The term “Board of Directors” means the Board of Directors of the Company. 
 (b) The term “Certificate of Incorporation” means the Third Amended and Restated Certificate of Incorporation of the Company of even date herewith. 

(c) The term “Common Stock” means the Common Stock, $0.001 par value per share, of the Company.

 (d) The term “Exchange Act” means the Securities Exchange Act of 1934, as amended. 

(e) The term “Form S-3” means such form under the Securities Act as in effect on the date hereof or any
registration form under the Securities Act subsequently adopted by the SEC which permits inclusion or incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

(f) The term “Holder” means any individual or entity owning or having the right to acquire Registrable
Securities or any assignee thereof in accordance with Section 1.11 hereof. 
 (g) The term “Major
Holder” means, other than Series C Investors who are not Existing Investors and Series B Investors who are not Existing Investors, each individual or entity owning at least 500,000 Registrable Securities (as adjusted for stock
splits, stock dividends, combinations and other recapitalizations), together with any of its general partners and affiliates. 

(h) The term “Majority Investors” means and includes Avalon Ventures IX, L.P. and each Permitted
Transferee thereof and MPM BioVentures V, L.P. and each Permitted Transferee thereof; provided, however, that to the extent that any of the foregoing entities ceases to hold shares of Series A Preferred Stock, Series B
Preferred Stock or Series C Preferred Stock, such entity shall no longer be a Majority Investor. 
 (i) The term
“Permitted Transferee” has the meaning set forth in the Stockholders’ Agreement. 
 (j) The
term “Qualifying IPO” means the firmly underwritten initial public offering of shares of Common Stock at a per share price not less than three (3) times the Series B Original Purchase Price (as defined in the
Certificate of Incorporation and as adjusted for stock splits, stock dividends, combinations and other recapitalizations) resulting in proceeds to the Company of at least $40,000,000 (before deducting any underwriting or similar commissions,
compensation or concessions paid or allowed by the Company in connection with such offering and any expenses payable by the Company in connection with such offering). 

  
 2 

 (k) The terms “register”,
“registered” and “registration” refer to a registration effected by preparing and filing a registration statement or similar document in compliance with the Securities Act, and the declaration or
ordering of effectiveness of such registration statement or document by the SEC. 
 (l) The term “Registrable
Securities” means all shares of Common Stock held by any Holder, including, but not limited to: (i) the Common Stock issuable or issued upon conversion of the Series C Preferred Stock, the Series B Preferred Stock, the
Series A Preferred Stock and the Series A-1 Preferred Stock; and (ii) any Common Stock of the Company issued as (or issuable upon the conversion or exercise of any warrant, right or other security which is issued as) a dividend or
other distribution with respect to, or in exchange for or in replacement of the shares referenced in clause “(i)” above, excluding in all cases, however, any Registrable Securities sold by a Holder in a transaction in which such
Holders’s rights under this Section 1 are not assigned and excluding Registrable Securities that have been sold in an offering registered under the Securities Act or in an open-market transaction under Rule 144 of the Securities Act.

 (m) The number of shares of “Registrable Securities then-outstanding” shall be determined by
the number of shares of Common Stock then-outstanding which are, and the number of shares of Common Stock issuable pursuant to then-exercisable or then-convertible securities which are, Registrable Securities. 

(n) The term “Registration Expenses” means all expenses incurred by the Company in complying with
Sections 1.2, 1.3 and 1.4 hereof, including, without limitation, all registration and filing fees, printing expenses, fees and disbursements of counsel for the Company, reasonable fees and disbursements of a single special counsel for the
Holders, blue sky fees and expenses and the expense of any special audits incident to or required by any such registration (but excluding the compensation of regular employees of the Company which shall be paid in any event by the Company).

 (o) The term “SEC” means the Securities and Exchange Commission. 

(p) The term “Securities Act” means the Securities Act of 1933, as amended. 

(q) The term “Selling Expenses” means all underwriting discounts and selling commissions applicable to a
sale of Registrable Securities. 
 (r) The term “Series A Directors” has the meaning set
forth in the Stockholders’ Agreement. 
 (s) The term “Series A Preferred Stock” means
the Series A Preferred Stock, par value $0.001 per share, of the Company. 
 (t) The term
“Series A-1 Preferred Stock” means the Series A-1 Preferred Stock, par value $0.001 per share, of the Company. 

  
 3 

 (u) The term “Series B Preferred Stock” means the
Series B Preferred Stock, par value $0.001 per share, of the Company. 
 (v) The term “Series C
Preferred Stock” means the Series C Preferred Stock, par value $0.001 per share, of the Company. 
 (w)
The term “Stockholders’ Agreement” means the Second Amended and Restated Stockholders’ Agreement, dated the date hereof, by and among the Company and the stockholders named therein. 

1.2 Demand Registration. 
 (a) After the earlier of (i) five (5) years after the date of the Prior Agreement or (ii) six (6) months after the effective date of a Qualifying IPO, if the Company receives a
written request from the Holders of at least a majority of the Registrable Securities then- outstanding that the Company file a registration statement under the Securities Act (provided that the anticipated aggregate offering price would exceed
$5,000,000), then the Company shall: 
 (i) within thirty (30) days of the receipt thereof, give written notice of
such request to all Holders; and 
 (ii) use its best efforts to effect, as soon as practicable after receipt of such
request, the registration under the Securities Act of that number of Registrable Securities which the Holders requested to be registered, subject to the limitations of Section 1.2(b), within thirty (30) days of the mailing of such notice
by the Company. 
 (b) If the Holders initiating the registration request hereunder (the “Initiating
Holders”) intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 1.2(a) and the Company shall
include such information in the written notice referred to in Section 1.2(a). In such event, the right of any Holder to include its Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such
underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting (unless otherwise mutually agreed by a majority in interest of the Initiating Holders and such Holder) to the extent provided herein. All Holders
proposing to distribute their securities through such underwriting shall (together with the Company as provided in Section 1.5(f)) enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such
underwriting; provided, however, that no Holder (or any of their assignees) shall be required to make any representations, warranties or indemnities except as they relate to such Holder’s ownership of shares and authority to enter
into the underwriting agreement and to such Holder’s intended method of distribution, and the liability of such Holder shall be limited to an amount equal to the net proceeds from the offering received by such Holder. Notwithstanding any other
provision of this Section 1.2, if the underwriter advises the Initiating Holders in writing that marketing factors require a limitation of the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of
Registrable Securities which would otherwise be underwritten pursuant hereto, and the number of shares of Registrable Securities that may be included in the underwriting shall be allocated among all Holders thereof, including the Initiating

  
 4 

 
Holders, in proportion (as nearly as practicable) to the amount of Registrable Securities of the Company owned by each Holder; provided, however, that the number of shares of
Registrable Securities to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. 
 (c) The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to this Section 1.2: 

(i) After the Company has effected two (2) registrations pursuant to this Section 1.2 and such registrations have been
declared or ordered effective; or 
 (ii) If the Company delivers notice to the Initiating Holders within thirty
(30) days of such Initiating Holders’ registration request that the Company intends to file the first registration statement for a public offering of securities of the Company (other than a registration statement relating either to the
sale of securities to employees of the Company pursuant to a stock option, stock purchase or similar plan or a transaction pursuant to Rule 145 of the Securities Act (“SEC Rule 145”)) within sixty (60) days
from the date of such notice. 
 1.3 Company Registration. 

(a) If (but without any obligation to do so) the Company proposes to register (including for this purpose a registration effected
by the Company for stockholders other than the Holders) any of its stock or other securities under the Securities Act in connection with the public offering of such securities solely for cash (other than a registration statement relating either to
the sale of securities to employees of the Company pursuant to a stock option, stock purchase or similar plan or an SEC Rule 145 transaction), the Company shall, at such time, promptly give each Holder written notice of such registration. Upon
the written request of each Holder given within twenty (20) days after mailing of such notice by the Company, the Company shall cause to be registered under the Securities Act all of the Registrable Securities that each such Holder has
requested to be registered. 
 (b) If the registration statement under which the Company gives notice under this
Section 1.3 is for an underwritten offering, the Company shall so advise the Holders of Registrable Securities. In such event, the right of any such Holder to be included in a registration pursuant to this Section 1.3 shall be conditioned
upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their Registrable Securities through
such underwriting shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting by the Company; provided, however, that no Holder (or any of their assignees) shall be
required to make any representations, warranties or indemnities except as they relate to such Holder’s ownership of shares and authority to enter into the underwriting agreement and to such Holder’s intended method of distribution, and the
liability of such Holder shall be limited to an amount equal to the net proceeds from the offering received by such Holder. Notwithstanding any other provision of the Agreement, if the underwriter determines in good faith that marketing factors
require a limitation of the number of shares to be underwritten, the number of shares that may be included in the underwriting shall be allocated: (i) first, to the Company; (ii) second, to the Holders on a pro

  
 5 

 
rata basis based on the total number of Registrable Securities held by the Holders; and (iii) third, to any stockholder of the Company (other than a Holder) on a pro rata basis. No such
reduction shall reduce the amount of securities of the selling Holders included in the registration below forty percent (40%) of the total amount of securities included in such registration, unless such offering is the Company’s initial
public offering of shares of Common Stock registered under the Securities Act and such registration does not include shares of any other selling stockholders, in which event any or all of the Registrable Securities of the Holders may be excluded in
accordance with the immediately preceding sentence at the underwriter’s discretion. In no event will shares of any other selling stockholder be included in such registration which would reduce the number of shares which may be included by
Holders without the written consent of Holders of not less than a majority of the Registrable Securities proposed to be sold in the offering. If any Holder disapproves of the terms of any such underwriting, such Holder may elect to withdraw
therefrom by written notice to the Company and the underwriter, delivered at least ten (10) business days prior to the effective date of the registration statement. Any Registrable Securities excluded or withdrawn from such underwriting shall
be excluded and withdrawn from the registration. For any Holder which is a partnership, limited liability company or corporation, the partners, retired partners, managers, members and stockholders of such Holder, or the estates and family members of
any such partners, members and retired partners and any trusts for the benefit of any of the foregoing persons shall be deemed to be a single “Holder”, and any pro rata reduction with respect to such “Holder” shall be based upon
the aggregate amount of shares carrying registration rights owned by all entities and individuals included in such “Holder”, as defined in this sentence. 
 1.4 Form S-3 Registration. In the event that the Company receives a written request from the Holders that the Company effect a registration on Form S-3 and any related qualification or compliance
with respect to all or a part of the Registrable Securities owned by such Holders, the Company will: 
 (a) promptly give
written notice of the proposed registration, and any related qualification or compliance, to all other Holders; and 
 (b)
as soon as practicable, effect such registration and all such qualifications and compliances as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Holder’s or Holders’
Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any other Holder or Holders joining in such request as are specified in a written request given within fifteen (15) days
after receipt of such written notice from the Company; provided, however, that the Company shall not be obligated to effect any such registration, qualification or compliance, pursuant to this Section 1.4: (i) if Form S-3 is
not available for such offering by the Holders; (ii) if the Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration, propose to sell Registrable Securities and such other securities
(if any) at an aggregate price to the public of less than $1,000,000; (iii) if the Company has, within the 12-month period preceding the date of such request, already effected two (2) registrations on Form S-3 for the Holders pursuant to
this Section 1.4; or (iv) in any particular jurisdiction in which the Company would be required to qualify to do business or to execute a general consent to service of process in effecting such registration, qualification or compliance.

  
 6 

 (c) Subject to the foregoing, the Company shall file a Form S-3 registration
statement covering the Registrable Securities and other securities so requested to be registered as soon as practicable after receipt of the request or requests of the Holders. Registrations effected pursuant to this Section 1.4 shall not be
counted as demands for registration or registrations effected pursuant to Sections 1.2 or 1.3, respectively. 
 1.5
Obligations of the Company. Whenever required under this Section 1 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities, use its best efforts to
cause such registration statement to become effective, and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one (1) year or
until the distribution contemplated in the registration statement has been completed; provided, however, that: (i) such one (1) year period shall be extended for a period of time equal to the period any Holder refrains from
selling any securities included in such registration at the request of the Company or any underwriter for the Company; and (ii) in the case of any registration of Registrable Securities on Form S-3 which are intended to be offered on a
continuous or delayed basis, such one (1) year period shall be extended, if necessary, to keep the registration statement effective until all such Registrable Securities are sold; 

(b) prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus used in
connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement; 

(c) furnish to the Holders such numbers of copies of a prospectus, including a preliminary prospectus, in conformity with the
requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them; 
 (d) use its best efforts to register and qualify the securities covered by such registration statement under such other securities or blue sky laws of such jurisdictions as shall be reasonably
requested by the Holders; provided, however, that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or
jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 
 (e) in the event of any order suspending the effectiveness of a registration statement, use its best efforts to obtain the withdrawal of such order at the earliest possible time; 

(f) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in
usual and customary form, with the managing underwriter of such offering; 

  
 7 

 (g) notify each Holder of Registrable Securities covered by a registration statement
at any time when a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue
statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing; 

(h) notify each Holder of Registrable Securities covered by a registration statement of: (i) the effectiveness of such
registration statement; (ii) the filing of any post- effective amendments to such registration statement; or (iii) the filing of a supplement to such registration statement; 

(i) make available for inspection, upon reasonable notice during the Company’s regular business hours, by each Holder of
Registrable Securities covered by a registration statement, any underwriter participating in any distribution pursuant to such registration statement, and any attorney, accountant or other agent retained by such Holder or underwriter, all material
financial and other records, pertinent corporate documents and properties of the Company, and cause the Company’s officers, directors and employees to supply all information reasonably requested by any such Holder, underwriter, attorney,
accountant or agent in connection with such registration statement; 
 (j) upon the transfer of shares by a Holder in
connection with a registration hereunder, furnish unlegended certificates representing ownership of the Registrable Securities being sought in such denominations as shall be requested by the Holders or the underwriters; 

(k) cause all such Registrable Securities registered pursuant hereunder to be listed on each securities exchange on which similar
securities issued by the Company are then listed; 
 (l) provide a transfer agent and registrar for all Registrable
Securities registered pursuant hereunder and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; and 
 (m) furnish, at the request of any Holder, on the date that such Holder’s Registrable Securities are delivered to the underwriters for sale in connection with a registration pursuant to this
Agreement, if such securities are being sold through underwriters, or, if such securities are not being sold through underwriters, on the date that the registration statement with respect to such securities becomes effective: (i) an opinion,
dated as of such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering and reasonably satisfactory to a majority in
interest of the Holders requesting registration, addressed to the underwriters and to the Holders requesting registration of Registrable Securities; and (ii) a “comfort” letter dated as of such date, from the independent certified
public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering and reasonably satisfactory to a majority in interest of the Holders
requesting registration, addressed to the underwriters and to the Holders requesting registration of Registrable Securities. 

  
 8 

 1.6 Furnish Information. 

(a) It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 1 with
respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as shall be
required to effect the registration of such Holder’s Registrable Securities. For the avoidance of doubt, the Company shall be entitled to exclude from any registration the Registrable Securities of any selling Holder that does not comply with
the provisions of this Section 1.6(a). 
 (b) The Company shall have no obligation with respect to any registration
requested pursuant to Section 1.2 if, due to the operation of Section 1.6(a), the number of shares or the anticipated aggregate offering price of the Registrable Securities to be included in the registration does not equal or exceed the
number of shares or the anticipated aggregate offering price required to originally trigger the Company’s obligation to initiate such registration as specified in Section 1.2(a). 

1.7 Expenses of Registration. Except as specifically provided herein, all Registration Expenses incurred in connection with any
registration, qualification or compliance pursuant to Section 1.2, Section 1.3 or Section 1.4 herein shall be borne by the Company. All Selling Expenses incurred in connection with any registrations hereunder, shall be borne by the
holders of the securities so registered pro rata on the basis of the number of shares so registered. 
 1.8
Indemnification. In the event any Registrable Securities are included in a registration statement under this Section 1: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each Holder, any underwriter (as defined in the Securities Act) for such Holder and each person, if any, who
controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any losses, claims, damages, or liabilities (joint or several) to which they may become subject under the Securities Act, the Exchange Act or
other federal or state law, insofar as such losses, claims, damages, or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively a
“Violation”): (i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement, including any preliminary prospectus or final prospectus contained therein or any amendments
or supplements thereto; (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the
Company of the Securities Act, the Exchange Act, any state securities law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law; and the Company will pay to each such Holder, underwriter or
controlling person any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity agreement

  
 9 

 
contained in this Section 1.8(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability, or action if such settlement is effected without the consent of the
Company (which consent shall not be unreasonably withheld), nor shall the Company be liable in any such case for any such loss, claim, damage, liability, or action to the extent that it arises out of or is based upon a Violation which occurs solely
in reliance upon and in conformity with written information furnished expressly for use in connection with such registration by any such Holder, underwriter or controlling person. 

(b) To the extent permitted by law, each selling Holder will, severally but not jointly, indemnify and hold harmless the Company,
each of its directors, each of its officers who has signed the registration statement, each person, if any, who controls the Company within the meaning of the Securities Act, any underwriter, any other Holder selling securities in such registration
statement and any controlling person of any such underwriter or other Holder, against any losses, claims, damages, or liabilities (joint or several) to which any of the foregoing persons may become subject, under the Securities Act, the Exchange Act
or other federal or state law, insofar as such losses, claims, damages, or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs
solely in reliance upon and in conformity with written information furnished by such Holder expressly for use in connection with such registration; and each such Holder will pay any legal or other expenses reasonably incurred by any person intended
to be indemnified pursuant to this Section 1.8(b), in connection with investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity agreement contained in this
Section 1.8(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and
provided further that, in no event shall any indemnity under this Section 1.8(b) exceed the net proceeds from the offering received by such Holder. 
 (c) Promptly after receipt by an indemnified party under this Section 1.8 of notice of the commencement of any action (including any governmental action), such indemnified party will, if a
claim in respect thereof is to be made against any indemnifying party under this Section 1.8, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and,
to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party
(together with all other indemnified parties which may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such
indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such proceeding. The failure
to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if prejudicial to its ability to defend such action, shall relieve such indemnifying party of any liability to the indemnified party
under this Section 1.8, but the omission to deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 1.8. 

  
 10 

 (d) If the indemnification provided for in this Section 1.8 is held by a court
of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage, or expense referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall
contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the
indemnified party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as any other relevant equitable considerations. The relative fault of the indemnifying party and
of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying party or
by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. 
 (e) Notwithstanding the foregoing, to the extent that the provisions relating to indemnification and contribution contained in the underwriting agreement entered into in connection with the
underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 
 (f) The obligations of the Company and Holders under this Section 1.8 shall survive the completion of any offering of Registrable Securities in a registration statement under this
Section 1. 
 1.9 Reports Under the Exchange Act. With a view to making available to the Holders the benefits of
Rule 144 promulgated under the Securities Act (“SEC Rule 144”) and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or
pursuant to a registration on Form S-3, the Company agrees to: 
 (a) make and keep public information available, as
those terms are understood and defined in SEC Rule 144, at all times after ninety (90) days after the effective date of the first registration statement filed by the Company for the offering of its securities to the general public (other
than a registration statement relating either to the sale of securities to employees of the Company pursuant to a stock option, stock purchase or similar plan or an SEC Rule 145 transaction); 

(b) take such action, including the voluntary registration of its Common Stock under Section 12 of the Exchange Act, as is
necessary to enable the Holders to utilize Form S-3 for the sale of their Registrable Securities, such action to be taken as soon as practicable after the end of the fiscal year in which the first registration statement filed by the Company for the
offering of its securities to the general public (other than a registration statement relating either to the sale of securities to employees of the Company pursuant to a stock option, stock purchase or similar plan or an SEC Rule 145
transaction) is declared effective; 
 (c) file with the SEC in a timely manner all reports and other documents required
of the Company under the Securities Act and the Exchange Act; and 

  
 11 

 (d) furnish to any Holder, so long as the Holder owns any Registrable Securities,
forthwith upon request: (i) a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the first registration statement filed
by the Company), the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after it so
qualifies); (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company; and (iii) such other information as may be reasonably requested in availing any Holder of
any rule or regulation of the SEC which permits the selling of any such securities without registration or pursuant to such form. 
 1.10 Limitation on Subsequent Registration Rights. After the date of this Agreement, the Company shall not, without the prior written consent of the Holders of at least a majority of the
Registrable Securities then-outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that would grant such holder registration rights pari passu or senior to those granted to the Holders
hereunder. 
 1.11 Assignment of Registration Rights. The rights to cause the Company to register Registrable Securities
pursuant to this Section 1 may be assigned (but only with all related obligations) by a Holder to one or more transferees or assignees of such securities (an “Assignee”): (i) to whom such Holder transfers such
securities pursuant to Section 3.2 hereof; (ii) who is an employee, affiliate or affiliated partnership managed by such Holder; or (iii) who, after such assignment or transfer, acquires at least ten percent (10%) (subject to
appropriate adjustment for stock splits, stock dividends, combinations and other recapitalizations) of the Registrable Securities held by the Holder as of the date of this Agreement, provided that (a) the Company is, within a reasonable time
after such transfer, furnished with written notice of the name and address of such Assignee and the securities with respect to which such registration rights are being assigned and (b) such Assignee agrees in writing to be bound by and subject
to the terms and conditions of this Agreement. 
 1.12 Termination of Registration Rights. No Holder shall be entitled to
exercise any right provided for in this Section 1 after five (5) years following the consummation of the sale of securities pursuant to a Qualifying IPO or, as to any Holder, such earlier time at which all Registrable Securities held by
such Holder (and any affiliate of the Holder with whom such Holder must aggregate its sales under SEC Rule 144) can be sold without restriction in any three (3) month period without registration in compliance with SEC Rule 144.

  

	2.	ADDITIONAL COVENANTS. 

2.1 Delivery of Financial Statements and Related Information. 

(a) The Company shall deliver, or make available on a secure password- protected website or otherwise, to each Major Holder, each
Series C Investor and each Series B Investor: 
 (i) as soon as practicable, but in any event within one
hundred twenty (120) days after the end of each fiscal year of the Company, an income statement for such fiscal 

  
 12 

 
year, a balance sheet of the Company and statement of stockholder’s equity as of the end of such year, and a schedule as to the sources and applications of funds for such year, such year-end
financial reports to be in reasonable detail, prepared in accordance with generally accepted accounting principles, and audited and certified by independent public accountants selected by the Company and approved by the Board of Directors; and

 (ii) as soon as practicable, but in any event within forty-five (45) days after the end of each quarter of each
fiscal year of the Company, an unaudited income statement for the relevant fiscal quarter, schedule as to the sources and application of funds for such fiscal quarter, and an unaudited balance sheet as of the end of such fiscal quarter, all prepared
in accordance with generally accepted accounting principles, except for any otherwise applicable footnote disclosures, and certified by the Company’s Chief Financial Officer (or person performing similar functions in the absence of a Chief
Financial Officer). 
 (b) The Company shall deliver, or make available on a secure password- protected website or
otherwise, to each Major Holder: 
 (i) as soon as practicable, but in any event within thirty (30) days prior to
the end of each fiscal year, a comprehensive operating budget approved by the Board of Directors, forecasting the Company’s revenues, expenses and cash position on a month-to-month basis for the upcoming fiscal year; 

(ii) as soon as practicable, but in any event within fifteen (15) days after the end of each quarter of each fiscal year of
the Company, a then current capitalization table of the Company certified by the Company’s Chief Financial Officer (or person performing similar functions in the absence of a Chief Financial Officer); and 

(iii) such other information relating to the financial condition, business, prospects or corporate affairs of the Company as
determined by the Board of Directors or as any such Major Holder may from time to time reasonably request. 
 (c)
Notwithstanding the foregoing, if the Board of Directors reasonably determines that the Company’s fulfillment of its obligations set forth in this Section 2.1 with respect to any specific Holder would be likely to result in a breach by
the Company of any non- disclosure obligation or other actual or potential conflict of interest, the Company shall have no obligation to such Holder with respect to this Section 2.1. 

2.2 Right of First Refusal. Subject to the terms and conditions specified in this Section 2.2, the Company hereby grants to
each Major Holder, each Series C Investor and each Series B Investor (collectively, the “ROFR Holders”) a right of first refusal with respect to future sales by the Company of Additional Shares of Common Stock (as
defined in the Certificate of Incorporation). Each Major Holder shall be entitled to apportion the right of first refusal hereby granted to it among itself and its partners and affiliates in such proportions as it deems appropriate. 

(a) Subject to Section 2.2(e), each time the Company proposes to offer any Additional Shares of Common Stock, the Company
shall first make an offering of such Additional Shares of Common Stock to each ROFR Holder in accordance with the following provisions: 
 (b) The Company shall deliver a notice in accordance with Section 4.3 below (the “Notice”) to each ROFR Holder stating: (i) its bona fide intention to offer such
Additional Shares of Common Stock; (ii) the number of such Additional Shares of Common Stock to be offered; and (iii) the price and terms, if any, upon which it proposes to offer such Additional Shares of Common Stock. 

  
 13 

 (c) Within seven (7) calendar days after delivery of the Notice in accordance
with Section 4.3 below, each ROFR Holder may elect to purchase or obtain, at the price and on the terms specified in the Notice, up to that portion of such Additional Shares of Common Stock which equals the proportion that the number of
Registrable Securities then held by such ROFR Holder bears to the total number of Registrable Securities then-outstanding. The Company shall promptly, in writing, inform each ROFR Holder that elects to purchase all of the Additional Shares of Common
Stock available to it (each, a “Participating ROFR Holder”) of any other ROFR Holder’s failure to do likewise. During the five (5) day period commencing after receipt of such notice, each Participating ROFR Holder
shall be entitled to obtain that portion of the Additional Shares of Common Stock for which ROFR Holders were entitled to, but did not, subscribe equal to the proportion that the number of Registrable Securities then held by such Participating ROFR
Holder bears to the total number of Registrable Securities then held by all Participating ROFR Holders who wish to purchase some of the unsubscribed Additional Shares of Common Stock. 

(d) If all Additional Shares of Common Stock that ROFR Holders are entitled to obtain pursuant to Section 2.2(b) are not
subscribed for as provided in Section 2.2(c), the Company may, during the sixty (60) day period following the expiration of the period provided in Section 2.2(c), offer the remaining unsubscribed portion of such Additional Shares of
Common Stock to any person or persons at a price not less than that, and upon terms no more favorable to such person or persons than those, specified in the Notice. If the Company does not enter into an agreement for the sale of the Additional
Shares of Common Stock within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such Additional Shares of Common Stock shall not
be offered unless first reoffered to the ROFR Holders in accordance herewith. 
 (e) The rights of first refusal of each
ROFR Holder under this Section 2.2 may be transferred to the same parties, subject to the same restrictions, as any transfer of registration rights pursuant to Section 1.11. 

2.3 Inspection Rights. Subject to the execution of reasonable nondisclosure agreements (if appropriate), each Major Holder shall
have the right to visit and inspect any of the properties of the Company, to discuss the affairs, finances and accounts of the Company with its officers, and to review such information as is reasonably requested all at such reasonable times (during
normal business hours) and as often as may be reasonably requested for any purpose reasonably related to such Major Holder’s interest as a stockholder of the Company; provided, however, that the Company shall not be obligated
under this Section 2.3 with respect to: (i) a 

  
 14 

 
competitor of the Company; (ii) information which the Board of Directors determines in good faith is confidential or attorney-client privileged and should not, therefore, be disclosed; or
(iii) any specific Holder if the Board of Directors reasonably determines that the Company’s fulfillment of its obligations set forth in this Section 2.3 with respect to such Holder would be disadvantageous to the Company, or be
likely to result in a breach by the Company of any non- disclosure obligation or other actual or potential conflict of interest. 
 2.4 D&O Insurance Coverage. The Company agrees to: (i) maintain a D&O insurance policy covering members of the Board of Directors (and their affiliated funds) and officers of the
Company in a reasonable amount satisfactory to the Majority Investors and on terms consistent with the NVCA VentureInsure product; and (ii) ensure that any successor of the Company or acquirer of all or substantially all of the Company’s
assets assumes the Company’s obligations with respect to indemnification of the members of the Board of Directors. 

2.5 Board of Directors Matters. Unless otherwise agreed by a majority of the members of the Board of Directors, including a
majority of the Series A Directors, meetings of the Board of Directors shall be held at least bimonthly. The Company shall reimburse all members of the Board of Directors for all reasonable travel expenses incurred by them in connection with
the attendance of meetings of the Board of Directors. 
 2.6 Employee Stock. Unless otherwise approved by the Board of
Directors, all recipients of options to purchase shares of the Company’s capital stock or similar equity awards after the date hereof shall be required to execute option agreements providing for vesting of shares over a four (4) year
period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment, and the remaining shares vesting in equal monthly installments over the following thirty-six (36) months.

 2.7 Termination of Certain Covenants. The covenants set forth in this Section 2 shall terminate and be of no
further force or effect upon the earlier of: (i) the consummation of the sale of securities pursuant to a Qualifying IPO; or (ii) the first date upon which none of the Registrable Securities are outstanding. 

 

	3.	RESTRICTIONS ON TRANSFER. 

3.1 General Restrictions. In addition to any restrictions set forth in the Stockholders’ Agreement, each Holder agrees not to
make any disposition of all or any portion of its Registrable Securities unless and until: 
 (a) There is then in effect
a registration statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with such registration statement; or 
 (b) (i) The transferee has agreed in writing to be bound by the terms of this Agreement; (ii) such Holder shall have notified the Company of the proposed disposition and shall have
furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition; and (iii) if reasonably requested by the Company, such Holder shall have furnished the Company with an opinion of counsel, reasonably
satisfactory to the Company, that such disposition will not require registration of such shares under the Securities Act. 

  
 15 

 3.2 Exceptions. Notwithstanding the provisions of Section 3.1, no such
restriction shall apply to a transfer by a Holder that is: (i) a partnership transferring to its partners or former partners in accordance with partnership interests; (ii) a corporation transferring to a wholly owned subsidiary or a parent
corporation that owns all of the capital stock of the Holder; (iii) a limited liability company transferring to its members or former members in accordance with their interest in the limited liability company; (iv) an individual
transferring to the Holder’s family member or trust for the benefit of an individual Holder or such Holder’s family member(s); (v) the Kansas Bioscience Authority (or its successor or replacement entity), to any successor or
replacement entity formed by or as an instrumentality or authority of the State of Kansas; or (vi) the Ewing Marion Kauffman Foundation (or its successor or replacement entity), to any successor or replacement entity formed by the Ewing Marion
Kauffman Foundation for the purpose of holding equity investments, or any entity under common investment management with any such successor or replacement entity; provided, however, that in each case the transferee will agree in
writing to be subject to the terms of this Agreement to the same extent as if he, she or it were an original Holder hereunder. 

3.3 Legends. Each certificate representing Registrable Securities shall be stamped or otherwise imprinted with a legend
substantially similar to the following (in addition to any legend required under applicable state securities laws): 
 THE SALE,
PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE TERMS AND CONDITIONS OF THAT CERTAIN INVESTORS’ RIGHTS AGREEMENT BY AND BETWEEN THE STOCKHOLDER AND THE COMPANY. COPIES OF SUCH AGREEMENT MAY
BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY. 
 3.4 Removal of Legends. The Company shall be
obligated to promptly reissue unlegended certificates at the request of any Holder thereof if the Company has completed the initial public offering of shares of Common Stock registered under the Securities Act and the Holder shall have obtained an
opinion of counsel (which counsel may be counsel to the Company) reasonably acceptable to the Company to the effect that the securities proposed to be disposed of may lawfully be so disposed of without registration, qualification and legend. In
addition, any legend endorsed on an instrument pursuant to applicable state securities laws and the stop-transfer instructions with respect to such securities shall be removed upon receipt by the Company of an order of the appropriate blue sky
authority authorizing such removal. 
  

	4.	MISCELLANEOUS. 

 4.1
Successors and Assigns. Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties (including transferees of any shares
of Registrable Securities). Nothing in this Agreement, express or implied, is intended to confer upon any party 

  
 16 

 
other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in
this Agreement. 
 4.2 Aggregation of Stock. All shares of Registrable Securities held or acquired by affiliated entities
or persons shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 

4.3 Notices. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (i) upon
personal delivery to the party to be notified; (ii) when sent by electronic mail or confirmed facsimile, if sent during normal business hours of the recipient or, if not, then on the next business day; (iii) five (5) days after having
been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All
communications shall be sent to the Company and to each of the Investors, as applicable, at the respective addresses set forth on the signature page of this document or at such other address(es) as the Company or any such Investor may designate by
ten (10) days advance written notice to the other parties hereto. 
 4.4 Expenses. If any action at law or in equity
is necessary to enforce or interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled.

 4.5 Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement
may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the Majority Investors. Notwithstanding the foregoing: (i) this Agreement may not be
amended or terminated and the observance of any term of this Agreement may not be waived with respect to any Investor without the written consent of such Investor unless such amendment, termination or waiver applies to all Investors in the same
fashion; (ii) this Agreement may be amended only with the written consent of the Company for the sole purpose of including additional purchasers of Series C Preferred Stock, Series B Preferred Stock or Series A Preferred Stock as
“Investors” hereunder; and (iii) the provisions of Section 2.2 may not be waived in respect of any transaction in which any Majority Investor (or an affiliate thereof) purchases securities of the Company unless each ROFR Holder
is given the right to purchase securities on a pro rata basis with such Majority Investor (including its affiliates), which right may be exercisable on reasonable notice in a subsequent closing occurring after the initial purchase of securities in
such transaction. Any amendment or waiver effected in accordance with this paragraph shall be binding upon each holder of any Registrable Securities then-outstanding, each future holder of all such Registrable Securities, and the Company.

 4.6 Severability. If one or more provisions of this Agreement are held by a court of competent jurisdiction to be
unenforceable under applicable legal requirements, the parties agree to promptly renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement in writing for such provision,
then: (i) such provision shall be excluded from this Agreement; (ii) the balance of this Agreement shall be interpreted as if such provision were so excluded; and (iii) the balance of this Agreement shall be enforceable in accordance
with its terms. 

  
 17 

 4.7 Governing Law. This Agreement shall be governed by and construed in accordance
with the General Corporation Law of the State of Delaware without reference to its principles of conflict of laws. 
 4.8
Entire Agreement. This Agreement, together with the exhibits and schedules hereto, constitutes the entire agreement among the parties, and no party shall be liable or bound to any other party in any manner by any warranties, representations, or
covenants except as specifically set forth herein or therein. 
 4.9 Counterparts; Execution by Facsimile. This Agreement
may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery of an executed counterpart of this Agreement by facsimile (or similar electronic
means) shall be equally as effective as delivery of an original executed counterpart of this Agreement. 
 [REMAINDER OF PAGE
INTENTIONALLY LEFT BLANK] 

  
 18 

 IN WITNESS WHEREOF, the parties have executed this SECOND AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT as of the date first written above. 
  

	
	COMPANY:
	
	ARATANA THERAPEUTICS, INC.
	
	 /s/ Steven St. Peter

	Steven St. Peter
	Chief Executive Officer

 

			
	Address:	 	1901 Olathe Boulevard
		 	Kansas City, KS 66103

  
 [SIGNATURE
PAGE TO SECOND AMENDED AND 
 RESTATED INVESTOR’S RIGHTS AGREEMENTS] 

 
			
	INVESTOR:
	
	AVALON VENTURES IX, L.P.
		
	By:	 	Avalon Ventures IX GP, LLC
	Its:	 	General Partner
	
	 /s/ Jay Lichter

	Name:	 	Jay Lichter
	Title:	 	Managing Member
		
	Address:	 	1134 Kline Street
		 	La Jolla, CA 92037
	
	INVESTOR:
	
	MPM BIOVENTURES V, L.P.
		
	By:	 	MPM BioVentures V GP LLC
	Its:	 	General Partner
		
	By:	 	MPM BioVentures V LLC
	Its:	 	Managing Member
	
	 /s/ John Vander Vort

	Name:	 	John Vander Vort
	Title:	 	Member
		
	Address:	 	200 Clarendon St. 54F
		 	Boston, MA 02116
	
	MPM ASSET MANAGEMENT INVESTORS BV5 LLC
		
	By:	 	MPM BioVentures V LLC
	Its:	 	Manager
	
	 /s/ John Vander Vort

	Name:	 	John Vander Vort
	Title:	 	Member
		
	Address:	 	200 Clarendon St. 54F
		 	Boston, MA 02116

  
 [SIGNATURE
PAGE TO 
 SECOND AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENTS] 

 
			
	INVESTOR:
	
	 MIDPOINT FOOD & AG FUND, LP

	(entity name if applicable)
		
	By:	 	 /s/ R. Meeusen

	(signature)
		
	Print Name:	 	 R. Meeusen

	Title:	 	 Partner

	(if applicable)
		
	Address:	 	11550 N. Meridian
		 	Carmel, IN 46033
	
	INVESTOR:
	
	 MIDPOINT FOOD & AG

	 CO-INVESTMENT FUND, LP

	(entity name if applicable)
		
	By:	 	 /s/ R. Meeusen

	(signature)
		
	Print Name:	 	 R. Meeusen

	Title:	 	 Partner

	(if applicable)
		
	Address:	 	11550 N. Meridian St.
		 	Carmel, IN 46032
	
	INVESTOR:
	
	 EWING MARION KAUFFMAN

	 FOUNDATION

	(entity name if applicable)
		
	By:	 	 /s/ Kristen Bechard

	(signature)
		
	Print Name:	 	 Kristen Bechard

	Title:	 	 Controller

	(if applicable)
		
	Address:	 	4801 Rockhill Road
		 	Kansas City, MO 64110

  
 [SIGNATURE
PAGE TO 
 SECOND AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENTS] 

 
			
	INVESTOR:
	
	 HALL FAMILY FOUNDATION

	(entity name if applicable)
		
	By:	 	 /s/ John A. MacDonald

	(signature)
		
	Print Name:	 	 John A. MacDonald

	Title:	 	 VP &Treasurer

	(if applicable)
		
	Address:	 	P.O. Box 419580
		 	Maildrop 323
		 	Kansas City, MO 64141
	
	INVESTOR:
	
	 MIDDLELAND AG FUND, LP

	(entity name if applicable)
		
	By:	 	 /s/ Brian Mixe

	(signature)
		
	Print Name:	 	 Brian Mixe

	Title:	 	 Manager, Middleland AG LLC, its

		 	 general partner

	(if applicable)
		
	Address:	 	888 16th St.
		 	Suite 800
		 	Washington, DC 20006

  
 [SIGNATURE
PAGE TO 
 SECOND AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENTS] 

 
			
	INVESTOR:
	
	 MID-AMERICA ANGELS INVESTMENTS,

	 LLC

	(entity name if applicable)
		
	By:	 	 /s/ Joel Wiggins

	(signature)
		
	Print Name:	 	 Joel Wiggins

	Title:	 	 Executive Manager

	(if applicable)
		
	Address:	 	8527 Bluejacket Street
		 	Lenexa, KS 66214
		 	PH: 913.438.2282
	
	INVESTOR:
	
	 MVA CAPITAL GROUP, LLC

	(entity name if applicable)
		
	By:	 	 /s/ Patricia L. Brasted

	(signature)
		
	Print Name:	 	 Patricia L. Brasted

	Title:	 	 Managing Member

	(if applicable)
		
	Address:	 	7829 E. Rockhill Rd. #307
		 	Wichita, KS 67206
	
	INVESTOR:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ William Gautreaux

	(signature)
		
	Print Name:	 	 William Gautreaux

	Title:	 	  

	(if applicable)
		
	Address:	 	200 W 54th St.
		 	Kansas City, MO 64112

  
 [SIGNATURE
PAGE TO 
 SECOND AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENTS] 

 
			
	INVESTOR:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Irv Hockaday

	(signature)
		
	Print Name:	 	 Irv Hockaday

	Title:	 	  

	(if applicable)
		
	Address:	 	2600 Grand Ave.
		 	Suite 450
		 	Kansas City, MO 64108
	
	INVESTOR:
	
	 GRASSMERE KANSAS ANGEL

	 INVESTMENTS, LLC

	(entity name if applicable)
		
	By:	 	 /s/ Peter C. Brown

	(signature)
		
	Print Name:	 	 Peter C. Brown

	Title:	 	 Chairman

	(if applicable)
		
	Address:	 	801 W. 47th St., Suite 400
		 	Kansas City, MO 64112
	
	INVESTOR:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ David Frantze

	(signature)
		
	Print Name:	 	 David Frantze

	Title:	 	  

	(if applicable)
		
	Address:	 	2200 W. 125th St.
		 	Leawood, KS 66209

  
 [SIGNATURE
PAGE TO 
 SECOND AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENTS] 

 
			
	INVESTOR:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Stephen A. Lightstone

	(signature)
		
	Print Name:	 	 Stephen A. Lightstone

	Title:	 	  

	(if applicable)
		
	Address:	 	4935 Central St.
		 	Kansas City, MO 64112
	
	INVESTOR:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ John Neil

	(signature)
		
	Print Name:	 	 John Neil

	Title:	 	  

	(if applicable)
		
	Address:	 	7445 East Butler Drive
		 	Scottsdale, AZ 85258
	
	INVESTOR:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Michael A. Driscoll

	(signature)
		
	Print Name:	 	 Michael A. Driscoll

	Title:	 	  

	(if applicable)
		
	Address:	 	823 Woodland Ave
		 	Oradell, NJ 07649

  
 [SIGNATURE
PAGE TO 
 SECOND AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENTS] 

 
			
	INVESTOR:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Chris McGrath

	(signature)
		
	Print Name:	 	 Chris McGrath

	Title:	 	  

	(if applicable)
		
	Address:	 	5078 Seashell Place
		 	San Diego, CA 92130
	
	INVESTOR:
	
	 KANSAS CENTER FOR

	 ENTREPRENEURSHIP

	(entity name if applicable)
		
	By:	 	 /s/ Patricia L. Brasted

	(signature)
		
	Print Name:	 	 Patricia L. Brasted

	Title:	 	 President and CEO of Wichita

		 	 Technology Corporation

	(if applicable)
		
	Address:	 	7829 E. Rockhill Rd., Suite 307
		 	Wichita, KS 67206
	
	INVESTOR:
	
	 LIMIT & CO

	(entity name if applicable)
		
	By:	 	 /s/ John A. MacDonald

	(signature)
		
	Print Name:	 	 John A. MacDonald

	Title:	 	 General Partner

	(if applicable)
		
	Address:	 	Chinquapin Trust Co.
		 	P.O. Box 419580, Mail Drop 323
		 	Kansas City, MO 64141

  
 [SIGNATURE
PAGE TO 
 SECOND AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENTS] 

 
			
	INVESTOR:
	
	 VIE VENTURE LLC

	(entity name if applicable)
		
	By:	 	 /s/ Steven St. Peter

	(signature)
		
	Print Name:	 	 Steven St. Peter

	Title:	 	 Member

	(if applicable)
		
	Address:	 	1901 Olathe Blvd
		 	Kansas City, KS 66103
	
	INVESTOR:
	
	 THE SANCHEZ FAMILY TRUST,

	 MARCH 31, 2011, CARL SANCHEZ AND

	 ANGELA ROMERO SANCHEZ,

	 TRUSTEES

	(entity name if applicable)
		
	By:	 	 /s/ Carl Sanchez

	(signature)
		
	Print Name:	 	 Carl Sanchez

	Title:	 	 Trustee

	(if applicable)
		
	Address:	 	1318 Summit Avenue
		 	Cardiff, CA 92007
	
	INVESTOR:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Robert F. Willamson

	(signature)
		
	Print Name:	 	 Robert F. Willamson

	Title:	 	  

	(if applicable)
		
	Address:	 	140 La Salle Ave
		 	Piedmont, CA 94610

  
 [SIGNATURE
PAGE TO 
 SECOND AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENTS] 

 
			
	INVESTOR:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Eric I. Richman

	(signature)
		
	Print Name:	 	 Eric I. Richman

	Title:	 	  

	(if applicable)
		
	Address:	 	9740 Sorrel Ave
		 	Potomac, MD 20854
	
	INVESTOR:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ William F. Hartfiel III

	(signature)
		
	Print Name:	 	 William F. Hartfiel III

	Title:	 	  

	(if applicable)
		
	Address:	 	2732 Thomas Ave South
		 	Minneapolis, MN 55416
	
	INVESTOR:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Richard A. Sapp

	(signature)
		
	Print Name:	 	 Richard A. Sapp

	Title:	 	  

	(if applicable)
		
	Address:	 	PO Box 1514
		 	Rancho Santa Fe, CA 92067-1514

  
 [SIGNATURE
PAGE TO 
 SECOND AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENTS] 

 
			
	INVESTOR:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Sanford J. Madigan

	(signature)
		
	Print Name:	 	 Sanford J. Madigan

	Title:	 	  

	(if applicable)
		
	Address:	 	12577 Kingspine Ave
		 	San Diego, CA 92131
	
	INVESTOR:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Gary William Pace

	(signature)
		
	Print Name:	 	 Gary William Pace

	Title:	 	  

	(if applicable)
		
	Address:	 	1405 Inspiration Dr.
		 	La Jolla, CA 92037
	
	INVESTOR:
	
	 CURTIS A. KRIZEK REVOCABLE

	 TRUST, UTA DTD 12/17/98

	(entity name if applicable)
		
	By:	 	 /s/ Curtis A. Krizek

	(signature)
		
	Print Name:	 	 Curtis A. Krizek

	Title:	 	 Trustee

	(if applicable)
		
	Address:	 	4900 Main Street, Suite 700
		 	Kansas City, MO 64112

  
 [SIGNATURE
PAGE TO 
 SECOND AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENTS] 

 
			
	INVESTOR:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Andrew S. Klocke

	(signature)
		
	Print Name:	 	 Andrew S. Klocke

	Title:	 	  

	(if applicable)
		
	Address:	 	8016 Cherokee Lane
		 	Leawood, KS 66206

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENTS] 

 
			
	INVESTOR:
	
	KANSAS BIOSCIENCE AUTHORITY
	
	 /s/ Duane Cantrell

	Name: Duane Cantrell
	Title: President and CEO
		
	Address:	 	10900 S. Clay Blair Blvd.
		 	Olathe, KS 66061

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 
			
	INVESTOR:
	
	  

	(entity name if applicable)
		
	By:	 	   /s/ Paul DeBruce

		 	(signature)
	Print Name:	 	   Paul DeBruce

	Title:	 	  

		 	(if applicable)
	
	Address:
	 411 Nichols Road, Suite 217

	 Kansas City, MO 64112

	  

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 
			
	INVESTOR:
	
	 UMB Bank, n.a, As Custodian For The Sheila Kemder Dietrich IRA

	(entity name if applicable)
		
	By:	 	   /s/ Robert Paredes

		 	(signature)
	Print Name:	 	   ROBERT PAREDES

	Title:	 	   V.P. / SR. Trust Advisor

		 	(if applicable)
	
	Address:
	 1010 Grand Boulevard

	 Kansas City, MO 64106

	  

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 
			
	INVESTOR:
	
	 Leerink Swann Holdings, LLC

	(entity name if applicable)
		
	By:	 	   /s/ Timothy A.G. Gerhold

		 	(signature)
	Print Name:	 	   Timothy A.G. Gerhold

	Title:	 	   General Counsel

		 	(if applicable)
	
	Address:
	 1 Federal St. Floor 37

	 Boston, MA 02110

	  

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 
			
	INVESTOR:
	
	 Leerink Swann Co-Investment Fund, LLC

	(entity name if applicable)
		
	By:	 	   /s/ Jeffrey A. Leerink

		 	(signature)
	Print Name:	 	   Jeffrey A. Leerink

	Title:	 	   Manager

		 	(if applicable)
	
	Address:
	 1 Federal St., 37th Floor

	 Boston, MA 02110

	  

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 
			
	INVESTOR:
	
	  

	(entity name if applicable)
		
	By:	 	   /s/ Louise Mawhinney

		 	(signature)
	Print Name:	 	   Louise Mawhinney

	Title:	 	  

		 	(if applicable)
	
	Address:
	 22 Frost Lane

	 Sudbury MA, 01776

	  

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 
			
	INVESTOR:
	
	 Christena A. Gautreaux Trust 2004

	(entity name if applicable)
		
	By:	 	   /s/ Christena A. Gautreaux

		 	(signature)

 
			
	Print Name:	 	   Christena A.
Gautreaux

 
			
	Title:	 	   Trustee

		 	(if applicable)
	
	Address:
	 200 west 54th St.

	 Kansas City MO. 64112

	  

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 
			
	INVESTOR:
	
	  

	(entity name if applicable)
		
	By:	 	   /s/ Erick Lucera

		 	(signature)
	Print Name:	 	   Erick Lucera

	Title:	 	    

	(if applicable)
	
	Address:
	 138 Thistle Road

	 North Andover, MA 01845

	  

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 
			
	INVESTOR:
	
	  

	(entity name if applicable)
		
	By:	 	   /s/ Julia Stephanus

		 	(signature)
	Print Name	 	   Julia Stephanus

	Title:	 	    Chief Commercial Officer

		 	(if applicable)
	
	Address:
	 21 Tolmadge Lane

	 Basking Ridge NJ 07920

	  

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 
			
	INVESTOR:
	
	  

	(entity name if applicable)
		
	By:	 	   /s/ Thomas L. Shoaf

		 	(signature)
	Print Name	 	   Thomas L. Shoaf

	Title:	 	  

		 	(if applicable)
	
	Address:
	 4224 Beverly Drive

	 Dallas TX 75205

	  

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 
			
	INVESTOR:
	
	  

	(entity name if applicable)
		
	By:	 	   /s/ John Fulton Murray III

		 	(signature)
	Print Name	 	   John Fulton Murray III

	Title:	 	  

		 	(if applicable)
	
	Address:
	 1 Westover Rd.

	 Fort Worth, TX 76107

	  

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 EXHIBIT A 
 SCHEDULE OF INVESTORS 
 Avalon Ventures IX, L.P. 

MPM BioVentures V, L.P. 
 MPM Asset Management
Investors BV5 LLC 
 MidPoint Food & Ag Fund, LP 
 MidPoint Food & Ag Co-Investment Fund, LP 
 Kansas Bioscience Authority 

RaQualia Pharma Inc. 
 Ewing Marion Kauffman
Foundation 
 Hall Family Foundation 

Middleland AG Fund, LP 
 Mid-America Angels
Investments, LLC 
 MVA Capital Group LLC 
 Paul DeBruce 
 Christena Gautreaux 
 Irv Hockaday 
 Grassmere Kansas Angel Investments, LLC 

Brian N Kaufman 
 Davfd W. Frantze 

The Maichen Family Trust Dated 7/ 13/99 
 Stephen
A. Lightstone 
 John Neil 
 Michael
Driscoll 
 Sheila Kemper Dietrich IRA 

Christopher H. McGrath 

 Kansas Center for Entrepreneurship, Inc. 
 William Gautreaux 
 Limit & Co. 
 Vie Venture LLC 
 The Sanchez Family Trust, March 31, 2011, Carl Sanchez and Angela Romero
Sanchez, Trustees 
 Robert F. Williamson 
 Eric I. Richman 
 William F. Hartfiel III 
 Richard A. Sapp 
 Sanford J. Madigan 
 Gary William Pace 
 Curtis A. Krizek Revocable Trust UTA Dtd 12/17/98 

Andrew S. Klocke 
 Leerink Swann Holdings, LLC

 Leerink Swann Co-Investment Fund, LLC 

Louise Mawhinney 
 Christena A. Gautreaux Trust
2004 
 Erick Lucera 
 Julia Stephanus

 Thomas L. Shoaf 
 John Fulton Murray
IIIEX-10.2

 Exhibit 10.2 
 SECOND AMENDED AND RESTATED 
 STOCKHOLDERS’ AGREEMENT 

THIS SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT (the “Agreement”) is made and entered into
as of December 28, 2012, by and among ARATANA THERAPEUTICS, INC., a Delaware corporation (the “Company”), each of the holders of Series C Preferred Stock (as defined below) listed on Exhibit A
hereto (the “Series C Preferred Holders”), each of the holders of Series B Preferred Stock (as defined below) listed on Exhibit B hereto (the “Series B Preferred
Holders”), each of the holders of Series A Preferred Stock (as defined below) listed on Exhibit C hereto (the “Series A Preferred Holders”), each of the holders of Series A-1 Preferred
Stock (as defined below) listed on Exhibit D hereto (the “Series A-1 Preferred Holders” and, together with the Series B Preferred Holders and the Series A Preferred Holders, the
“Preferred Holders”), each of the holders of Common Stock (as defined below) listed on Exhibit E hereto (the “Common Holders” and collectively with the Series A Preferred Holders and
the Series A-1 Preferred Holders, the “Existing Holders”) and each Additional Holder (as defined below) who shall, after the date hereof, acquire shares of Common Stock and become a party to this Agreement as a
“Common Holder” by executing and delivering to the Company an Instrument of Accession in the form of Exhibit F hereto. The Common Holders (including any Additional Holders) and the Preferred Holders are sometimes refereed to
herein individually as a “Stockholder” and collectively as the “Stockholders”. 

RECITALS 

WHEREAS, the Company and the Series A Preferred Holders are parties to that certain Series A Preferred Stock Purchase
Agreement, dated as of December 27, 2010 (the “Series A Purchase Agreement”), and the Company and the Series A-1 Preferred Holders are parties to that certain Series A-1 Preferred Stock Purchase Agreement,
dated as of December 27, 2010 (the “Series A-1 Purchase Agreement” and, together with the Series A Purchase Agreement, the “Prior Purchase Agreements”); 

WHEREAS, as a condition of entering into the Prior Purchase Agreements, the Existing Holders and the Company executed that certain
Stockholders’ Agreement dated as of December 27, 2010 among the Company and the Existing Holders (the “Prior Agreement”); 
 WHEREAS, the Series B Preferred Holders are parties to that certain Series B Preferred Stock Purchase Agreement, dated as of November 1, 2011, among the Company and the Series B
Preferred Holders (the “Series B Purchase Agreement”); 
 WHEREAS, as a condition of
entering into the Series B Purchase Agreement the Series B Preferred Holders, the Existing Holders and the Company executed that certain First Amended and Restated Stockholders’ Agreement, dated as of November 1, 2011 (the
“Restated Prior Agreement”); 
 WHEREAS, the Series C Preferred Holders are parties to that
certain Series C Preferred Stock Purchase Agreement of even date herewith among the Company and the Series C Preferred Holders (the “Series C Purchase Agreement”); and 

 WHEREAS, the Series C Preferred Holders have requested that the Company and
Series B Preferred Holders and Existing Holders representing at least the Majority Investors (as defined in the Restated Prior Agreement) amend and restate the Restated Prior Agreement as set forth below, as an inducement to the Series C
Preferred Holders to enter into the Series C Purchase Agreement. 
 NOW THEREFORE, in consideration of the foregoing
recitals and the mutual promises, representations, warranties, and covenants hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Series B Preferred Holders and
the Existing Holders hereby agree that the Restated Prior Agreement shall be amended and restated, and the parties to this Agreement further agree as follows: 
 AGREEMENT 
 1. CERTAIN DEFINITIONS. For purposes of this Agreement: 

1.1 The term “Avalon Major Investor” shall mean, collectively, Avalon Ventures IX, L.P. and each Permitted
Transferee (as defined below) thereof. 
 1.2 The term “Certificate of Incorporation” shall mean
that certain Third Amended and Restated Certificate of Incorporation of the Company of even date herewith. 
 1.3 The
term “Company Transaction” shall mean any: (i) acquisition of the Company by another entity or person unaffiliated with any Stockholder by means of any transaction or series of related transactions (including, without
limitation, any reorganization, merger, consolidation, tender offer or stock sale) that results in the transfer of at least a majority of the then-outstanding voting power of the Company; or (ii) sale of all or substantially all of the assets
of the Company to an entity or person unaffiliated with any Stockholder. 
 1.4 The term “Major
Holders” shall have the meaning set forth in that certain Second Amended and Restated Investors’ Rights Agreement, dated as of even date herewith, by and among the Company and the investors named therein. 

1.5 The term “Majority Investors” shall mean and include the Avalon Major Investor and the MPM Major
Investor; provided, however, that to the extent that any of the foregoing ceases to hold shares of Series A Preferred Stock, Series B Preferred Stock or Series C Preferred Stock, such entity shall no longer be a Majority
Investor. 
 1.6 The term “Major Series B Subject Holders” shall mean Subject Holders who
hold at least 333,333 shares of Series B Preferred Stock. 
 1.7 The term “Major Series C Subject
Holders” shall mean Subject Holders who hold at least 250,000 shares of Series C Preferred Stock. 
 1.8
The term “MPM Major Investor” shall mean, collectively, MPM BioVentures V, L.P. and each Permitted Transferee thereof. 

  
 2 

 1.9 The term “Restricted Holder” shall mean and include the
Common Holders (including any Additional Holders), the Subject Holders (as defined below) and the Series A-1 Preferred Holders. 
 1.10 The term “Series A Directors” shall mean and includes the Avalon Director (as defined below), the MPM Director (as defined below) and the Additional Series A
Director (as defined below). 
 1.11 The term “Subject Holders” shall mean the Series C
Preferred Holders who are not Existing Holders or affiliates of Existing Holders and the Series B Preferred Holders who are not Existing Holders or affiliates of Existing Holders. 
 2. VOTING OF STOCKHOLDER SHARES. 
 2.1 Shares Held Subject to
Agreement. Each of the Stockholders agrees to hold all shares of capital stock of the Company registered in its respective name or beneficially owned by it as of the date hereof and any and all other securities of the Company legally or
beneficially acquired by it after the date hereof, including, without limitation, any shares of capital stock issuable upon exercise or conversion of securities exercisable for or convertible into shares of the Company’s capital stock
(hereinafter collectively referred to as the “Stockholder Shares”) subject to, and, at any time when entitled, to vote the Stockholder Shares in accordance with, the provisions of this Section 2. 

2.2 Size of Board of Directors. Subject to Section 2.3(a), each Stockholder shall, at all times when entitled to vote or give
a written consent with respect to such matter, vote at all regular or special meetings of stockholders, and shall give written consent with respect to, all Stockholder Shares so as to set and maintain the number of authorized directors comprising
the Company’s Board of Directors (the “Board of Directors”) at seven (7) directors. 
 2.3
Election of Directors. 
 (a) At each election of directors in which the holders of the Company’s Common Stock
(the “Common Stock”), the holders of the Company’s Series C Preferred Stock (the “Series C Preferred Stock”), the holders of the Company’s Series B Preferred Stock (the
“Series B Preferred Stock”), the holders of the Company’s Series A Preferred Stock (the “Series A Preferred Stock”) and/or the holders of the Company’s Series A-1
Preferred Stock (the “Series A-1 Preferred Stock” ), whether voting together as a single class or each voting as a separate class, are entitled to elect directors of the Company, the Stockholders shall, at all times when
entitled to vote or give a written consent with respect to, vote (or shall consent to vote pursuant to an action by written consent of the holders of capital stock of the Company) all of their respective Stockholder Shares so as to elect:

 (i) for so long as the Avalon Major Investor is a Majority Investor, one (1) designee of the Avalon Major
Investor (the “Avalon Director”), which designee shall initially be Jay Lichter, to serve as one (1) of the three (3) directors to be elected by the holders of a majority of the then-outstanding shares of
Series A Preferred Stock, voting as a separate class; 

  
 3 

 (ii) for so long as the MPM Major Investor is a Majority Investor, one
(1) designee of the MPM Major Investor (the “MPM Director”), which designee shall initially be John Vander Vort, to serve as one (1) of the three (3) directors to be elected by the holders of a majority of the
then-outstanding shares of Series A Preferred Stock, voting as a separate class; 
 (iii) one (1) designee
that is designated by the holders of at least seventy-five percent (75%) of the then-outstanding shares of Series A Preferred Stock (the “Additional Series A Director”), which designee shall initially be Ron
Meeusen, to serve as one (1) of the three (3) directors to be elected by the holders of a majority of the then-outstanding shares of Series A Preferred Stock, voting as a separate class; 

(iv) one (1) designee that is designated by the holders of a majority of the then-outstanding shares of Series C
Preferred Stock and Series B Preferred Stock, voting together as a single class on an as-if-converted to Common Stock basis (the “Series B/C Director”) to serve as one (1) of the remaining directors, which
designee shall initially be Linda Rhodes; 
 (v) one (1) designee that is designated by the holders of a majority
of the then-outstanding shares of Common Stock held by the Common Holders, which designee shall in all cases be the person serving as the Chief Executive Officer of the Company (the “CEO Director”), which shall initially be
Steven St. Peter, to serve as one (1) of the remaining directors; and 
 (vi) other designees that are acceptable
to a majority of the Series A Directors as independent members of the Board of Directors (the “Independent Directors”), which designees shall initially be Craig Tooman and Rip Gerber, to serve as the remaining directors.

 (b) Any vote taken to remove any director elected pursuant to this Section 2.3, or to fill any vacancy created by
the resignation, removal or death of a director elected pursuant to this Section 2.3, shall also be subject to the provisions of this Section 2.3. 
 (c) None of the parties hereto and no officer, director, stockholder, partner, employee or agent of any such party makes any representation or warranty as to the fitness or competence of the
nominee of any party hereunder to serve on the Board of Directors by virtue of such party’s execution of this Agreement or by the act of such party in voting for such nominee pursuant to this Agreement. 

(d) The Company agrees that it shall, at the request of any Stockholder or group of Stockholders entitled to designate directors
pursuant to Section 2.3(a), promptly take all actions necessary (pursuant to the Company’s bylaws, the laws of the State of Delaware or otherwise) to call and conduct a special meeting of the stockholders of the Company for the purpose of
electing directors in accordance with the provisions of Section 2.3(a). 
 2.4 Drag Along. 

(a) In the event that the Board of Directors and the Majority Investors approve any Company Transaction, each Stockholder will
vote (to the extent such Stockholder is entitled 

  
 4 

 
to vote) for, consent to and raise no objections to such Company Transaction. Each Stockholder will waive any dissenter’s rights, appraisal rights or similar rights, to the extent
applicable, in connection with any such Company Transaction. If the Company Transaction is structured as a sale of stock, each Stockholder will agree to sell all of its Stockholder Shares and rights to acquire Stockholder Shares pursuant to the
terms and conditions approved by the Board of Directors and the Majority Investors. Each Stockholder will take all necessary or desirable actions in connection with the consummation of the Company Transaction as requested by the Board of Directors
and the Majority Investors including, without limitation, delivering such Stockholder’s stock certificates free and clear of all liens and encumbrances (other than those arising under applicable securities laws). 

(b) Notwithstanding the foregoing Section 2.4(a), a Stockholder will not be required to comply with Section 2.4(a) in
connection with any Company Transaction unless: 
 (i) any representations and warranties to be made by such Stockholder
in connection with the Company Transaction are limited to representations and warranties related to authority, ownership and the ability to convey title to such Stockholder Shares, including but not limited to representations and warranties that:
(w) the Stockholder holds all right, title and interest in and to the Stockholder Shares such Stockholder purports to hold, free and clear of all liens and encumbrances; (x) the obligations of the Stockholder in connection with the Company
Transaction have been duly authorized, if applicable; (y) the documents to be entered into by the Stockholder have been duly executed by the Stockholder and delivered to the acquirer and are enforceable against the Stockholder in accordance
with their respective terms; and (z) neither the execution and delivery of documents to be entered into in connection with the Company Transaction, nor the performance of the Stockholder’s obligations thereunder, will cause a breach or
violation of the terms of any agreement, law or judgment, order or decree of any court or governmental agency; 
 (ii)
the Stockholder shall not be liable for the inaccuracy of any representation or warranty made by any other individual or entity (other than the Company) in connection with the Company Transaction; 

(iii) the liability for indemnification, if any, of such Stockholder in the Company Transaction and for the inaccuracy of any
representations and warranties made by the Company or breaches by the Company of its covenants made in any acquisition agreement in connection with such Company Transaction, is several and not joint with any other individual or entity and is pro
rata in proportion to, and does not exceed, the amount of consideration paid to such Stockholder in connection with such Company Transaction; and 
 (iv) The consideration paid to the Stockholders will be distributed pursuant to Section 3 of the Certificate of Incorporation, as if such Company Transaction were an Acquisition. 

2.5 Vote to Increase Authorized Common Stock. Each Stockholder shall, at all times when entitled to vote with respect to such
matter, vote (or shall, at all times when entitled to vote with respect to such matter, consent to vote pursuant to an action by written consent of the holders of capital stock of the Company) all of its respective Stockholder Shares as shall be

  
 5 

 
necessary to increase the number of authorized shares of Common Stock from time to time to ensure that there are sufficient shares of Common Stock available for conversion of all of the shares of
Series C Preferred Stock, Series B Preferred Stock, Series A Preferred Stock and Series A-1 Preferred Stock outstanding at any such time. 
 2.6 Irrevocable Proxy. Each Stockholder hereby constitutes and appoints the CEO Director as the attorney and proxy of such Stockholder, with full power of substitution, with respect to the matters
set forth in this Section 2, and hereby authorizes the CEO Director to represent and to vote all of the Stockholder Shares held by such Stockholder in accordance with the provisions set forth in this Section 2; provided,
however, that such proxy shall be in effect and exercisable if and only if the Stockholder granting such proxy: (i) fails to vote altogether on a matter covered by this Section 2; or (ii) attempts to vote on a matter covered by
this Section 2 in a manner other than as provided by this Section 2. The proxy granted pursuant to this Section 2.6 is coupled with an interest and shall be irrevocable unless and until the provisions of this Section 2 terminate
pursuant to the provisions of Section 2.7 below. Each Stockholder hereby revokes any and all previous proxies granted with respect to the Stockholder Shares held by such Stockholder and agrees not to grant any other proxy or power of attorney
with respect to such Stockholder Shares or to deposit any of such Stockholder Shares into a voting trust or to enter into any similar agreement, arrangement or understanding with any other person with respect to the voting of any Stockholder Shares
held by such Stockholder unless and until the provisions of this Section 2 terminate pursuant to the provisions of Section 2.7 below. 
 2.7 Termination of Voting Provisions. The provisions of this Section 2 shall continue in full force and effect from the date hereof through the earliest of the following dates, on which date
such provisions shall terminate and cease to be in effect: (i) the date of the closing of a firmly underwritten public offering of the Common Stock pursuant to a registration statement filed with the Securities and Exchange Commission (the
“SEC”) and declared effective under the Securities Act of 1933, as amended (the “Securities Act”); or (ii) the date of the closing of a sale, lease or other disposition of all or substantially all
of the Company’s assets or the Company’s merger into or consolidation with any other corporation or other entity, or any other corporate reorganization, in which the holders of the Company’s outstanding voting stock immediately prior
to such transaction own, immediately after such transaction, securities representing less than fifty percent (50%) of the voting power of the corporation or other entity surviving such transaction; provided, however, that this
clause “(ii)” shall not apply to a merger effected exclusively for the purpose of changing the domicile of the Company. 
 3.
RESTRICTIONS ON TRANSFERS BY STOCKHOLDERS. 
 3.1 General Restriction. Each Restricted Holder agrees that such
Restricted Holder shall not sell, assign, transfer, pledge, hypothecate, mortgage or dispose of, by gift or otherwise, or in any way encumber (collectively, “Transfer”), all or any part of the Stockholder Shares held by such
Stockholder other than in compliance with Sections 3.2 and 3.3 below. 

  
 6 

 3.2 Right of First Refusal. 

(a) Subject to Section 3.8 below, if at any time any Restricted Holder desires to Transfer in any manner any Stockholder
Shares held by such Restricted Holder pursuant to the terms of a bona fide written offer received from a third party (the “Restricted Holder Buyer”), such Restricted Holder (the “Selling Restricted
Holder”) shall submit a written offer (the “Restricted Holder Offer”) to sell such Stockholder Shares (the “Offered Stockholder Shares”) to the Company at the same price and on the same
terms and conditions on which the Selling Restricted Holder proposes to sell such Offered Stockholder Shares to the Restricted Holder Buyer. The Restricted Holder Offer shall disclose the identity of the proposed Restricted Holder Buyer, the number
of Offered Stockholder Shares, the terms of the proposed Transfer, including price, and any other material facts, terms and conditions relating to the proposed Transfer. Within thirty (30) days after receipt of the Restricted Holder Offer, the
Company shall give notice to the Selling Restricted Holder of its intent to purchase all or a portion of the Offered Stockholder Shares from the Selling Restricted Holder on the terms and conditions set forth in the Restricted Holder Offer. Such
notice shall specify the time, place and date for settlement of such purchase, which shall be consummated at a closing held at the Company within the thirty (30) day period specified above. 

(b) If the Company does not elect to purchase all of the Offered Stockholder Shares as provided in Section 3.2(a), the
Company shall, within five (5) days after expiration of the thirty (30) day period specified in Section 3.2(a), provide each Major Holder with written notice (the “ROFR Notice”) of such election, which ROFR
Notice shall include a copy of the Restricted Holder Offer provided to the Company pursuant to Section 3.2(a). Each Major Holder shall then have the right, exercisable within thirty (30) days following receipt of the ROFR Notice, to
purchase up to that number of the Offered Stockholder Shares that the Company elected not to purchase from such Selling Restricted Holder (all such remaining shares being referred to as the “Remaining Offered Stockholder
Shares”) equal to the aggregate Remaining Offered Stockholder Shares multiplied by a fraction: (i) the numerator of which is the number of Stockholder Shares held by such Major Holder; and (ii) the denominator of which is the
aggregate number of Stockholder Shares held by all of the Major Holders (such amount to be referred to as a Major Holder’s “Major Holder ROFR Pro Rata Share”). In the event that a Major Holder does not wish to purchase
its full Major Holder ROFR Pro Rata Share, then any Major Holder who has elected to purchase its full Major Holder ROFR Pro Rata Share shall have the right to purchase, on a pro rata basis with any other Major Holders who so elect, any Remaining
Offered Stockholder Shares not purchased. If exercised by the Major Holders pursuant hereto, the right to purchase the Offered Stockholder Shares or the Remaining Offered Stockholder Shares, as the case may be, shall be exercised by written notice,
signed by the Company and the participating Major Holders, and delivered to the Selling Restricted Holder prior to the expiration of the thirty (30) day notice period specified above. Such notice shall specify the time, place and date for
settlement of such purchase, which shall be consummated at a closing held at the Company within ten (10) days after the expiration of the thirty (30) day notice period specified above. 

(c) For the purposes of this Section 3.2, the number of Stockholder Shares held by a Major Holder shall include the holdings
of Permitted Transferees of such Major Holder, and such holdings shall be aggregated together with that of such Major Holder. As used 

  
 7 

 
in this Agreement, the term “Permitted Transferee” means: (i) in the case of a Stockholder that is a partnership, any constituent partner of such partnership and any
affiliated partnership, limited liability company or other entity managed by the same management company or general partner or any affiliate of such management company or general partner; (ii) in the case of a Stockholder that is a limited
liability company, any member of such limited liability company and any affiliated limited liability company, partnership or other entity managed by the same management company or member or any affiliate of such management company or member;
(iii) in the case of a Stockholder that is an individual, the spouse, children, grandchildren or spouse of such children or grandchildren of such person or to trusts for the benefit of such person or such person’s spouse, children,
grandchildren or spouse of such children or grandchildren; (iv) in the case of a Stockholder that is a trust, any beneficiary of such trust; (v) in the case of the Kansas Bioscience Authority (or its successor or replacement entity), any
successor or replacement entity formed by or as an instrumentality or authority of the State of Kansas; (vi) in the case of the Ewing Marion Kauffman Foundation (or its successor or replacement entity), to any successor or replacement entity
formed by the Ewing Marion Kauffman Foundation for the purpose of holding equity investments, or any entity under common investment management with any such successor or replacement entity; and (vii) in the case of a Company Transaction
approved by the Board of Directors and the Majority Investors pursuant to Section 2.4, the transferee approved by the Board of Directors and the Majority Investors pursuant to the terms and conditions approved by the Board of Directors and the
Majority Investors. 
 (d) Except as set forth in Section 3.8 below, in the event that the Company and the Major
Holders, on a collective basis, do not elect to purchase all of the Offered Stockholder Shares pursuant to and within the time periods set forth above, then the Company and the Stockholders shall be deemed to have forfeited any right to purchase the
Offered Stockholder Shares, and, subject to Section 3.3 and Section 3.8, the Selling Restricted Holder shall be free for a period of sixty (60) days thereafter, to sell all, but not less than all, of the Offered Stockholder Shares to
the Restricted Holder Buyer, if the Restricted Holder Buyer agrees in writing to be bound by the terms of this Agreement in the same capacity as the Selling Restricted Holder. Any such Transfer shall be at the same price per share, and upon the same
terms and conditions, as specified in the Restricted Holder Offer. Any Offered Stockholder Shares not sold within such sixty (60) day period shall thereafter again be subject to the requirements of this Section 3.2. 

3.3 Right of Co-Sale. If at any time any Selling Restricted Holder desires to Transfer in any manner any Stockholder Shares
pursuant to the terms of a Restricted Holder Offer received from a Restricted Holder Buyer, then each Major Holder shall have the right (the “Right of Co-Sale”) to require, as a condition to the Transfer, that the Restricted
Holder Buyer purchase from such Major Holder, at the same price per share and on the same terms and conditions as involved in such sale or disposition by the Selling Restricted Holder, that percentage of Stockholder Shares owned by such Major Holder
equal to a fraction: (i) the numerator of which is the number of Stockholder Shares held by such Major Holder; and (ii) the denominator of which is the sum of (a) the aggregate number of Stockholder Shares held by the Major Holders
and (b) the aggregate number of Stockholder Shares then held by the Selling Restricted Holder (such percentage hereinafter referred to as a Major Holder’s “Co-Sale Pro Rata Percentage”). To the extent that a Major
Holder does not exercise its Right of Co-Sale or elects to sell less than its full Co-Sale Pro Rata Percentage pursuant to this Section 3.3, the 

  
 8 

 
Selling Restricted Holder shall be entitled to sell to the Restricted Holder Buyer, at any time within sixty (60) days of the expiration of the rights granted pursuant to Section 3.2
and this Section 3.3, on the terms set forth in the Restricted Holder Offer, that number Stockholder Shares determined based on the portion of such Stockholder’s Co-Sale Pro Rata Percentage not sold pursuant to this Section 3.3. Any
Offered Stockholder Shares not sold within such sixty (60) day period shall thereafter again be subject to the requirements of this Section 3.3. 
 3.4 Exceptions to Restrictions. The restrictions on a Restricted Holder’s ability to Transfer Stockholder Shares contained in this Section 3 shall not apply to: (i) any Transfer of
Stockholder Shares by a Stockholder to any Permitted Transferee; or (ii) any Transfer of Stockholder Shares to the Company (or any assignee of the Company) pursuant to the terms of a stock restriction or stock repurchase agreement approved by
the Board of Directors which provides for such sale upon the termination of a Stockholder’s service with the Company. In the event of any Transfer pursuant to the foregoing clause “(i)”, the Permitted Transferee of the Stockholder
Shares shall hold the Stockholder Shares so acquired with all the rights conferred by, and subject to all the restrictions imposed by, this Agreement and such Permitted Transferee shall agree in writing to be bound by the terms of this Agreement in
the same capacity as the Stockholder. 
 3.5 Termination. The restrictions on a Restricted Holder’s ability to
Transfer Stockholder Shares contained in this Section 3 shall terminate upon the earlier of: (i) the date of the closing of a firmly underwritten public offering of the Common Stock pursuant to a registration statement filed with the SEC
and declared effective under the Securities Act; or (ii) the date of the closing of a sale, lease, or other disposition of all or substantially all of the Company’s assets or the Company’s merger into or consolidation with any other
corporation or other entity, or any other corporate reorganization, in which the holders of the Company’s outstanding voting stock immediately prior to such transaction own, immediately after such transaction, securities representing less than
fifty percent (50%) of the voting power of the corporation or other entity surviving such transaction; provided, however, that this clause “(ii)” shall not apply to a merger effected exclusively for the purpose of
changing the domicile of the Company. 
 3.6 Additional Holders. As a condition to the issuance by the Company to any
individual or entity (each, an “Additional Holder”) of Stockholder Shares (or rights or options to acquire Stockholder Shares), the Company shall require such Additional Holder to become a party to this Agreement as an
additional “Series C Preferred Holder,” “Series B Preferred Holder,” “Series A Preferred Holder,” “Series A-1 Preferred Holder” or “Common Holder,” as applicable, hereunder via
the execution and delivery to the Company of an Instrument of Accession in the form attached hereto as Exhibit F. 

3.7 “Market Stand-Off” Agreement. Each Stockholder hereby agrees that such Stockholder shall not sell, transfer, make
any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, any Stockholder Shares held by such Stockholder (other than those included in the registration) for a
period specified by the representative of the underwriters of Common Stock (or other securities) of the Company not to exceed one hundred eighty (180) days (or such other period as may be requested by the Company or an underwriter to
accommodate regulatory restrictions on (1) the 

  
 9 

 
publication or other distribution of research reports and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE
Rule 472(f)(4), or any successor provisions or amendments thereto), following the effective date of a registration statement of the Company filed under the Securities Act relating to the initial public offering of shares of Common Stock registered
under the Securities Act; provided, however, that all officers and directors of the Company and Stockholders of at least one percent (1%) of the Company’s voting securities enter into similar agreements. The Company may
impose stop-transfer instructions with respect to any Stockholder Shares subject to the foregoing restriction until the end of such one hundred eighty (180) day period (or such other period as may be requested by the Company or an underwriter
to accommodate regulatory restrictions on (1) the publication or other distribution of research reports and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or
NYSE Rule 472(f)(4), or any successor provisions or amendments thereto). Each Stockholder agrees that any transferee of any Stockholder Shares shall be bound by this Section 3.7. The underwriters of the Company’s stock are intended
third-party beneficiaries of this Section 3.7 and shall have the right, power and authority to enforce the provisions hereof as though they were parties hereto. Any discretionary waiver or termination of the restrictions of any or all of such
agreements by the Company or the underwriters shall apply pro rata to all Stockholders subject to such agreements, based on the number of Stockholder Shares subject to such agreements. 

3.8 Additional Restrictions on Subject Holders. No Subject Holder may Transfer all or any part of the Series C Preferred
Stock or the Series B Preferred Stock held by such Subject Holder prior to December 31, 2014 (the “Trigger Date”), except in the case of a Transfer to a Permitted Transferee; provided, however, that, upon the
Company’s receipt of prior written notice thereof from the Subject Holder, the Board of Directors may approve or reject a proposed Transfer other than to a Permitted Transferee prior to the Trigger Date in its sole discretion. On and after the
Trigger Date (or prior to the Trigger Date with the approval of the Board of Directors pursuant to the immediately preceding sentence), each Subject Holder may Transfer all or any part of its Series C Preferred Stock or Series B Preferred
Stock by following the procedure described in Section 3.2 above; provided, however, that notwithstanding Section 3.2(d) above, in the event that the Company and the Major Holders, on a collective basis, do not elect to purchase all of the
Offered Stockholder Shares pursuant to and within the time periods set forth in Section 3.2, then the provisions of Section 3.2(d) shall not apply but, instead, the Subject Holder may submit a written request to the Board of Directors for
its approval of the Restricted Holder Offer containing the information required to be contained in the Restricted Holder Offer pursuant to Section 3.2(a) above and any other information that may be reasonably required by the Board of Directors
(the “Request”) and thereafter, subject to Section 3.3, may Transfer the remaining Offered Stockholder Shares to the Restricted Holder Buyer only if the Board of Directors has issued to the Subject Holder a written
consent to such Request (the “Consent”) and then only in accordance with the terms of the Consent and of this Agreement. The Board of Directors may withhold or delay such Consent for reasonable business reasons for a period
of up to twelve (12) months following the submission of the Request. Any Consent shall lapse sixty (60) days after the date of the Consent. Any Offered Stockholder Shares not sold within such sixty (60) day period shall thereafter
again by subject to the requirements of this Section 3.8. 

  
 10 

 3.9 Option Upon Involuntary Transfer. Each Subject Holder or its
legal representative shall notify the Company in writing (the “Involuntary Transfer Notice”) promptly upon the occurrence, or any event that may lead to the occurrence, of an involuntary Transfer of all or a portion of its
Stockholder Shares (the “Involuntary Transfer Shares”) by operation of law to any person other than to the Company or the Major Holders in accordance with this Section 3 (including, without limitation, to a
Stockholder’s trustee in bankruptcy, to a purchaser at a creditor’s or court sale, pursuant to the death of a Stockholder, pursuant to a divorce, or to the guardian or conservator of an incompetent or incapacitated Stockholder) (an
“Involuntary Transfer”). The Company shall have the option to purchase all or a portion of the Involuntary Transfer Shares by delivering notice of its election to exercise such option to the person to whom the Involuntary
Transfer Shares were, or are to be, Transferred (the “Involuntary Transferee”) within thirty (30) days after its receipt of the Involuntary Transfer Notice. If the Company does not elect to purchase all of the
Involuntary Transfer Shares, the Company shall, within five (5) days after the expiration of the thirty (30) day notice period specified above, provide each Major Holder with written notice of such election, which notice shall include a
copy of the Involuntary Transfer Notice. Each Major Holder shall then have the right, exercisable within thirty (30) days following receipt of such notice, to purchase up to that number of the Involuntary Transfer Shares that the Company
elected not to purchase (all such remaining shares being referred to as the “Remaining Involuntary Transfer Shares”) equal to the aggregate Remaining Involuntary Transfer Shares multiplied by such Major Holder’s Major
Holder ROFR Pro Rata Share. In the event that a Major Holder does not wish to purchase its full Major Holder ROFR Pro Rata Share, then any Major Holder who has elected to purchase its full Major Holder ROFR Pro Rata Share shall have the right to
purchase, on a pro rata basis with any other Major Holders who so elect, any Remaining Involuntary Transfer Shares not purchased. If any of the foregoing options are timely exercised, the Involuntary Transferee shall sell to the Company or the Major
Holders, as applicable, and the Company or the Major Holders, as applicable, shall purchase from the Involuntary Transferee, such Involuntary Transfer Shares for a purchase price equal to fifty percent (50%) of the Fair Market Value (as defined
below) of a single Involuntary Transfer Share as of the date of the Involuntary Transfer multiplied by the number of Involuntary Transfer Shares being purchased. At its option, the Company or any purchasing Major Holder may elect to purchase
Involuntary Transfer Shares by the delivery of a promissory note in a principal amount equal to the purchase price, which amount shall be payable in full no later than the second (2nd) anniversary of the issuance thereof and may be prepaid in whole or in part at any time at the option of the
maker. For the purposes of this Section 3.9, “Fair Market Value” means the fair market value of each Involuntary Transfer Share, as determined in good faith by the Board of Directors. The Company’s or the Major
Holder’s, as applicable, exercise notice shall specify the time, place and date for settlement of such purchase, which shall be consummated at a closing held within the time period specified above. If the Company and the Major Holders, on a
collective basis, do not elect to purchase all of the Involuntary Transfer Shares pursuant to and within the time periods set forth above, any remaining Involuntary Transfer Shares shall be Transferred to the Involuntary Transferee subject
thereafter to all provisions of this Agreement. 

  
 11 

 4. MISCELLANEOUS. 
 4.1 Legends. 
 (a) Concurrently with the execution of this
Agreement, there shall be imprinted or otherwise placed, on each certificate representing Stockholder Shares, the following restrictive legend (the “Legend”): 

“THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS AND CONDITIONS OF A STOCKHOLDERS’ AGREEMENT WHICH PLACES
CERTAIN RESTRICTIONS ON THE SALE OR TRANSFER OF THE SHARES REPRESENTED HEREBY. ANY PERSON ACCEPTING ANY INTEREST IN SUCH SHARES SHALL BE DEEMED TO AGREE TO AND SHALL BECOME BOUND BY ALL THE PROVISIONS OF SUCH AGREEMENT. A COPY OF SUCH
STOCKHOLDERS’ AGREEMENT WILL BE FURNISHED TO THE RECORD HOLDER OF THIS CERTIFICATE WITHOUT CHARGE UPON WRITTEN REQUEST TO THE COMPANY AT ITS PRINCIPAL PLACE OF BUSINESS.” 

(b) The Company agrees that, during the term of this Agreement, it will not remove, and will not permit to be removed (upon
registration of transfer, reissuance or otherwise), the Legend from any certificate representing Stockholder Shares and will place or cause to be placed the Legend on any new certificate issued to represent Stockholders Shares theretofore
represented by a certificate carrying the Legend. 
 4.2 Successors. The applicable provisions of this Agreement shall be
binding upon the successors in interest to any of the Stockholder Shares. The Company shall not permit the Transfer of any of the Stockholder Shares on its books or issue a new certificate representing any of the Stockholder Shares unless and until
the person to whom such security is to be transferred shall have executed an Instrument of Accession in the form attached hereto as Exhibit F, pursuant to which such person becomes a party to this Agreement and agrees to be bound by all
the provisions hereof. 
 4.3 Specific Performance. The parties acknowledge and agree that it is impossible to measure in
money the damages which will accrue to a party hereto or to their heirs, personal representatives, or assigns by reason of a failure to perform any of the obligations under this Agreement and therefore agree that the terms of this Agreement shall be
specifically enforceable. If any party hereto or its heirs, personal representatives, or assigns institutes any action or proceeding to specifically enforce the provisions hereof, any person against whom such action or proceeding is brought hereby
waives the claim or defense therein that such party or such personal representative has an adequate remedy at law, and such person shall not offer in any such action or proceeding the claim or defense that such remedy at law exists. 

  
 12 

 4.4 Expenses. If any action at law or in equity is necessary to enforce or interpret
the terms of this Agreement, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 

4.5 Amendment and Waiver. Any provision of this Agreement may be amended and the observance thereof may be waived (either
generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Company and the Majority Investors. Notwithstanding the foregoing: (i) this Agreement may be amended only with the written
consent of the Company for the sole purpose of including Additional Holders as “Series C Preferred Holders,” “Series B Preferred Holders,” “Series A Preferred Holders,” “Series A-1 Preferred
Holders” or “Common Holders” hereunder; (ii) this Agreement may be amended only with the written consent of the Company for the sole purpose of including additional purchasers of Series C Preferred Stock as
“Series C Preferred Holders” hereunder, additional purchasers of Series B Preferred Stock as “Series B Preferred Holders” hereunder or additional purchasers of Series A Preferred Stock as “Series A
Preferred Holders” hereunder; and (iii) this Agreement may not be amended or terminated and the observance of any term of this Agreement may not be waived with respect to any Stockholder without the written consent of such Stockholder
unless such amendment, termination or waiver applies to all Stockholders in the same fashion. 
 4.6 Notices. All notices
required in connection with this Agreement shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified; (ii) when sent by electronic mail or confirmed facsimile, if sent during normal
business hours of the recipient; if not, then on the next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one (1) day after deposit with
a nationally recognized overnight courier, specifying next day delivery, with written notification of receipt. All communications shall be sent to the holder appearing on the books of the Company or at such address as such party may designate by ten
(10) days advance written notice to the other parties hereto. 
 4.7 Severability. If one or more provisions of this
Agreement are held by a court of competent jurisdiction to be unenforceable under applicable legal requirements, the parties agree to promptly renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable
and enforceable replacement in writing for such provision, then: (i) such provision shall be excluded from this Agreement; (ii) the balance of this Agreement shall be interpreted as if such provision were so excluded; and (iii) the
balance of this Agreement shall be enforceable in accordance with its terms. 
 4.8 Governing Law. This Agreement shall
be governed by and construed in accordance with the General Corporation Law of the State of Delaware without reference to its principles of conflict of laws. 
 4.9 Entire Agreement. This Agreement, together with the exhibits and schedules hereto, constitutes the entire agreement among the parties, and no party shall be liable or bound to any other party
in any manner by any warranties, representations, or covenants except as specifically set forth herein or therein. 

  
 13 

 4.10 Counterparts; Execution by Facsimile. This Agreement may be executed in two or
more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery of an executed counterpart of this Agreement by facsimile (or similar electronic means) shall be equally
as effective as delivery of an original executed counterpart of this Agreement. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

  
 14 

 
			
	STOCKHOLDER:
	
	AVALON VENTURES IX, L.P.
		
	By:	 	Avalon Ventures IX GP, LLC
	Its:	 	General Partner
	
	 /s/ Jay Lichter

	Name:	 	Jay Lichter
	Title:	 	Managing Member
		
	Address:	 	1134 Kline Street
		 	La Jolla, CA 92037
	
	STOCKHOLDER:
	
	MPM BIOVENTURES V, L.P.
		
	By:	 	MPM BioVentures V GP LLC
	Its:	 	General Partner
		
	By:	 	MPM BioVentures V LLC
	Its:	 	Managing Member
	
	 /s/ John Vander Vort

	Name:	 	John Vander Vort
	Title:	 	Member
		
	Address:	 	200 Clarendon St. 54F
		 	Boston, MA 02116
	
	MPM ASSET MANAGEMENT INVESTORS
	BV5 LLC
		
	By:	 	MPM BioVentures V LLC
	Its:	 	Manager
	
	 /s/ John Vander Vort

	Name:	 	John Vander Vort
	Title:	 	Member
		
	Address:	 	200 Clarendon St. 54F
		 	Boston, MA 02116

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDER’S AGREEMENT] 

 
			
	STOCKHOLDER:
	
	 MIDPOINT FOOD & AG FUND, LP

	(entity name if applicable)
		
	By:	 	 /s/ R. Meeusen

	(signature)
		
	Print Name:	 	 R. Meeusen

	Title:	 	 Partner

	(if applicable)
		
	Address:	 	11550 N. Meridian
		 	Carmel, IN 46033
	
	STOCKHOLDER:
	
	 MIDPOINT FOOD & AG

	 CO-INVESTMENT FUND, LP

	(entity name if applicable)
		
	By:	 	 /s/ R. Meeusen

	(signature)
		
	Print Name:	 	 R. Meeusen

	Title:	 	 Partner

	(if applicable)
		
	Address:	 	11550 N. Meridian St.
		 	Carmel, IN 46032
	
	STOCKHOLDER:
	
	 EWING MARION KAUFFMAN

	 FOUNDATION

	(entity name if applicable)
		
	By:	 	 /s/ Kristen Bechard

	(signature)
		
	Print Name:	 	 Kristen Bechard

	Title:	 	 Controller

	(if applicable)
		
	Address:	 	4801 Rockhill Road
		 	Kansas City, MO 64110

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDER’S AGREEMENT] 

 
			
	STOCKHOLDER:
	
	 HALL FAMILY FOUNDATION

	(entity name if applicable)
		
	By:	 	 /s/ John A. MacDonald

	(signature)
		
	Print Name:	 	 John A. MacDonald

	Title:	 	 VP &Treasurer

	(if applicable)
		
	Address:	 	P.O. Box 419580
		 	Maildrop 323
		 	Kansas City, MO 64141
	
	STOCKHOLDER:
	
	 MIDDLELAND AG FUND, LP

	(entity name if applicable)
		
	By:	 	 /s/ Brian Mixe

	(signature)
		
	Print Name:	 	 Brian Mixe

	Title:	 	 Manager, Middleland AG LLC, its

general partner

	(if applicable)
		
	Address:	 	888 16th St.
		 	Suite 800
		 	Washington, DC 20006

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDER’S AGREEMENT] 

 
			
	STOCKHOLDER:
	
	 MID-AMERICA ANGELS INVESTMENTS,

LLC

	(entity name if applicable)
		
	By:	 	 /s/ Joel Wiggins

	(signature)
		
	Print Name:	 	 Joel Wiggins

	Title:	 	 Executive Manager

	(if applicable)
		
	Address:	 	8527 Bluejacket Street
		 	Lenexa, KS 66214
		 	PH: 913.438.2282
	
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ William Gautreaux

	(signature)
		
	Print Name:	 	 William Gautreaux

	Title:	 	  

	(if applicable)
		
	Address:	 	200 W 54th St.
		 	Kansas City, MO 64112
	
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Irv Hockaday

	(signature)
		
	Print Name:	 	 Irv Hockaday

	Title:	 	  

	(if applicable)
		
	Address:	 	2600 Grand Ave.
		 	Suite 450
		 	Kansas City, MO 64108

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDER’S AGREEMENT] 

 
			
	STOCKHOLDER:
	
	 GRASSMERE KANSAS ANGEL

INVESTMENTS, LLC

	(entity name if applicable)
		
	By:	 	 /s/ Peter C. Brown

	(signature)
		
	Print Name:	 	 Peter C. Brown

	Title:	 	 Chairman

	(if applicable)
		
	Address:	 	801 W. 47th St., Suite 400
		 	Kansas City, MO 64112
	
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ David Frantze

	(signature)
		
	Print Name:	 	 David Frantze

	Title:	 	  

	(if applicable)
		
	Address:	 	2200 W. 125th St.
		 	Leawood, KS 66209
	
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Stephen A. Lightstone

	(signature)
		
	Print Name:	 	 Stephen A. Lightstone

	Title:	 	  

	(if applicable)
		
	Address:	 	4935 Central St.
		 	Kansas City, MO 64112

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDER’S AGREEMENT] 

 
			
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Michael A. Driscoll

	(signature)
		
	Print Name:	 	 Michael A. Driscoll

	Title:	 	  

	(if applicable)
		
	Address:	 	823 Woodland Ave
		 	Oradell, NJ 07649
	
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Chris McGrath

	(signature)
		
	Print Name:	 	 Chris McGrath

	Title:	 	  

	(if applicable)
		
	Address:	 	5078 Seashell Place
		 	San Diego, CA 92130
	
	STOCKHOLDER:
	
	 LIMIT &CO

	(entity name if applicable)
		
	By:	 	 /s/ John A. MacDonald

	(signature)
		
	Print Name:	 	 John A. MacDonald

	Title:	 	 General Partner

	(if applicable)
		
	Address:	 	Chinquapin Trust Co.
		 	P.O. Box 419580, Mail Drop 323
		 	Kansas City, MO 64141

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDER’S AGREEMENT] 

 
			
	STOCKHOLDER:
	
	 VIE VENTURE LLC

	(entity name if applicable)
		
	By:	 	 /s/ Steven St. Peter

	(signature)
		
	Print Name:	 	 Steven St. Peter

	Title:	 	 Member

	(if applicable)
		
	Address:	 	1901 Olathe Blvd
		 	Kansas City, KS 66103
	
	STOCKHOLDER:
	
	 THE SANCHEZ FAMILY TRUST,

MARCH 31, 2011, CARL SANCHEZ AND

ANGELA ROMERO SANCHEZ,
 TRUSTEES

	(entity name if applicable)
		
	By:	 	 /s/ Carl Sanchez

	(signature)
		
	Print Name:	 	 Carl Sanchez

	Title:	 	 Trustee

	(if applicable)
		
	Address:	 	1318 Summit Avenue
		 	Cardiff, CA 92007
	
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Robert F. Willamson

	(signature)
		
	Print Name:	 	 Robert F. Willamson

	Title:	 	  

	(if applicable)
		
	Address:	 	140 La Salle Ave
		 	Piedmont, CA 94610

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDER’S AGREEMENT] 

 
			
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Eric I. Richman

	(signature)
		
	Print Name:	 	 Eric I. Richman

	Title:	 	  

	(if applicable)
		
	Address:	 	9740 Sorrel Ave
		 	Potomac, MD 20854
	
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ William F. Hartfiel III

	(signature)
		
	Print Name:	 	 William F. Hartfiel III

	Title:	 	  

	(if applicable)
		
	Address:	 	2732 Thomas Ave South
		 	Minneapolis, MN 55416
	
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Richard A. Sapp

	(signature)
		
	Print Name:	 	 Richard A. Sapp

	Title:	 	  

	(if applicable)
		
	Address:	 	PO Box 1514
		 	Rancho Santa Fe, CA 92067-1514

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDER’S AGREEMENT] 

 
			
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Sanford J. Madigan

	(signature)
		
	Print Name:	 	 Sanford J. Madigan

	Title:	 	  

	(if applicable)
		
	Address:	 	12577 Kingspine Ave
		 	San Diego, CA 92131
	
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Gary William Pace

	(signature)
		
	Print Name:	 	 Gary William Pace

	Title:	 	  

	(if applicable)
		
	Address:	 	1405 Inspiration Dr.
		 	La Jolla, CA 92037
	
	STOCKHOLDER:
	
	 CURTIS A. KRIZEK REVOCABLE

TRUST, UTA DTD 12/17/98

	(entity name if applicable)
		
	By:	 	 /s/ Curtis A. Krizek

	(signature)
		
	Print Name:	 	 Curtis A. Krizek

	Title:	 	 Trustee

	(if applicable)
		
	Address:	 	4900 Main Street, Suite 700
		 	Kansas City, MO 64112

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDER’S AGREEMENT] 

 
			
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Andrew S. Klocke

	(signature)
		
	Print Name:	 	 Andrew S. Klocke

	Title:	 	  

	(if applicable)
		
	Address:	 	8016 Cherokee Lane
		 	Leawood, KS 66206
	
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ John Neil

	(signature)
		
	Print Name:	 	 John Neil

	Title:	 	  

	(if applicable)
		
	Address:	 	7445 East Butler Drive
		 	Scottsdale, AZ 85258
	
	STOCKHOLDER:
	
	 MVA CAPITAL GROUP, LLC

	(entity name if applicable)
		
	By:	 	 /s/ Patricia L. Brasted

	(signature)
		
	Print Name:	 	 Patricia L. Brasted

	Title:	 	 Managing Member

	(if applicable)
		
	Address:	 	7829 E. Rockhill Rd. #307
		 	Wichita, KS 67206

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDER’S AGREEMENT] 

 
			
	STOCKHOLDER:
	
	 KANSAS CENTER FOR

	 ENTREPRENEURSHIP

	(entity name if applicable)
		
	By:	 	 /s/ Patricia L. Brasted

	(signature)
		
	Print Name:	 	 Patricia L. Brasted

	Title:	 	 President and CEO of Wichita

		 	 Technology Corporation

	(if applicable)
		
	Address:	 	7829 E. Rockhill Rd., Suite 307
		 	Wichita, KS 67206
	
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ David K. Rosen

	(signature)
		
	Print Name:	 	 David K. Rosen

	Title:	 	  

	(if applicable)
		
	Address:	 	85 Kendal Court
		 	Guilford, CT 06437
	
	STOCKHOLDER:
	
	STEVEN ST. PETER
	
	 /s/ Steven St. Peter

		
	Address:	 	43 Union Park #2
		 	Boston, MA 02118

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDER’S AGREEMENT] 

 
			
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Linda Rhodes

	(signature)
		
	Print Name:	 	 Linda Rhodes

	Title:	 	 Chief Scientific Officer

	(if applicable)
		
	Address:	 	3 White Birch Ln
		 	Holmdel, NJ 07733

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDER’S AGREEMENT] 

 
			
	STOCKHOLDER:
	
	KANSAS BIOSCIENCE AUTHORITY
	
	 /s/ Duane Cantrell

	Name:	 	Duane Cantrell
	Title:	 	President and CEO
		
	 Address:
	 	 10900 S. Clay Blair Blvd.

Olathe, KS 66061

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

 
			
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Paul DeBruce

	(signature)
		
	Print Name:	 	 Paul DeBruce

	Title:	 	  

	(if applicable)
		
	Address:	 	411 Nichols Road, Suite 217
		 	Kansas City, MO 64112

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

 
			
	STOCKHOLDER:
	
	 UMB BANK, N.A., AS CUSTODIAN FOR

	 THE SHEILA KEMPER DIETRICH IRA

	(entity name if applicable)
		
	By:	 	 /s/ Robert Paredes

	(signature)
		
	Print Name:	 	 ROBERT PAREDES

	Title:	 	 V.P. / SR. TRUST ADVISOR

		 	(if applicable)
		
	 Address:
	 	1010 GRAND BOULEVARD
		 	KANSAS CITY, MO 64106

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

 
			
	STOCKHOLDER:
	
	 Leerink Swann Holdings, LLC

	(entity name if applicable)
		
	By	 	 /s/ Timothy A. G. Gerhold

	(signature)
		
	Print Name:	 	 TIMOTHY A. G. GERHOLD

	Title:	 	 GENERAL COUNSEL

	(if applicable)
		
	Address:	 	1 Federal St. 37th Floor
		 	Boston, MA 02110

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

			
	STOCKHOLDER:
	
	 Leerink Swann Co-Investment Fund, LLC

	(entity name if applicable)
		
	By:	 	 /s/ Jeffrey A. Leerink

	(signature)
		
	Print Name:	 	 Jeffrey A. Leerink

	Title:	 	 Manager

	(if applicable)
		
	Address:	 	
	 1 Federal St., 37th Floor

	 Boston, MA 02110

	

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

			
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Louise Mawhinney

	(signature)
		
	Print Name:	 	 LOUISE MAWHINNEY

	Title:	 	  

	(if applicable)
		
	Address:	 	22 FROST LANE
		 	SUDBURY, MA 01776

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

 
			
	STOCKHOLDER:
	
	Christena A. Gautreaux Trust 2004
	(entity name if applicable)
		
	By:	 	 /s/ C Gautreaux

	(signature)
		
	Print Name:	 	 Christena Gautreaux

	Title:	 	 Trustee

	(if applicable)
		
	Address:	 	200 West 54th St.
		 	KANSAS City, MO 64112

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

 
			
	STOCKHOLDER:
	
	  
	(entity name if applicable)
		
	By:	 	 /s/ Erick Lucera

	(signature)
		
	Print Name:	 	 Erick Lucera

	Title:	 	      

	(if applicable)
		
	Address:	 	138 Thistle Road
		 	North Andover, MA 01845

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

 
			
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Julia Stephanus

	(signature)
		
	Print Name:	 	 Julia Stephanus

	Title:	 	 Chief Commercial Officer Aratana Therapeutics

		 	(if applicable)
		
	Address:	 	21 Talmadge Lane
		 	Basking Ridge, NJ 07920

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

 
			
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Thomas L. Shoaf

	(signature)
		
	Print Name:	 	 Thomas L. Shoaf

	Title:	 	  

	(if applicable)
		
	Address:	 	4224 Beverly Drive
		 	Dallas TX 75205

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDER’S AGREEMENT] 

	
	STOCKHOLDER:
	
	  

	(entity name if applicable)

 
			
		
	By	 	 /s/ Fulton Murray III

	(signature)
		
	Print Name:	 	 John Fulton Murray III

	Title:	 	  

	(if applicable)
		
	Address:	 	7 Westover Rd
		 	Ft Worth TX 76107

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

 EXHIBIT A 
 SERIES C PREFERRED HOLDERS 
 Avalon Ventures IX, L.P. 

MPM Bio Ventures V, L.P. 
 MPM Asset Management
Investors BV5 LLC 
 MidPoint Food & Ag Fund, LP 
 MidPoint Food & Ag Co-Investment Fund, LP 
 Hall Family Foundation 

Middleland AG Fund, LP 
 Mid-America Angels
Investments, LLC 
 William Gautreaux 

Irv Hockaday 
 Grassmere Kansas Angel
Investments, LLC 
 David W. Frantze 

Stephen A. Lightstone 
 Michael A. Driscoll

 Christopher H. McGrath 
 Limit &
Co. 
 Vie Venture LLC 
 The Sanchez
Family Trust, March 31, 2011, Carl Sanchez and Angela Romero Sanchez, Trustees 
 Robert F. Williamson 

Eric I. Richman 
 William F. Hartfiel III

 Richard A. Sapp 
 Sanford J. Madigan

 Gary William Pace 

 Curtis A. Krizek Revocable Trust UTA Dtd 12/17/98 
 Andrew S. Klocke 
 John Neil 
 Ewing Marion Kauffman Foundation 
 Kansas Bioscience Authority 

Paul DeBruce 
 UMB Bank, N.A., as Custodian for
the Sheila Kemper Dietrich IRA 
 Leerink Swann Holdings, LLC 
 Leerink Swann Co-Investment Fund, LLC 
 Louise Mawhinney 

Christena A. Gautreaux Trust 2004 
 Erick Lucera

 Julia Stephanus 
 Thomas L. Shoaf

 John Fulton Murray III 

 EXHIBIT B 

SERIES B PREFERRED HOLDERS 
 Avalon Ventures IX, L.P. 
 MPM BioVentures V, L.P. 

MPM Asset Management Investors BV5 LLC 

MidPoint Food & Ag Fund, LP 
 MidPoint
Food & Ag Co-Investment Fund, LP 
 Kansas Bioscience Authority 
 Ewing Marion Kauffman Foundation 
 Hall Family Foundation 

Middleland AG Fund, LP 
 Mid-America
Angels Investments, LLC 
 MVA Capital Group LLC 
 Paul DeBruce 
 Christena Gautreaux 
 Irv Hockaday 
 Grassmere Kansas Angel Investments, LLC 

Brian N. Kaufman 
 David W. Frantze

 The Maichen Family Trust Dated 7/13/99 
 Stephen A. Lightstone 
 John Neil 
 Michael A. Driscoll 
 Sheila Kemper Dietrich IRA 

Christopher H. McGrath 
 Kansas Center for
Entrepreneurship, Inc. 

 EXHIBIT C 

SERIES A PREFERRED HOLDERS 
 Avalon Ventures IX, L.P. 
 MPM BioVentures V, L.P. 

MPM Asset Management Investors BV5 LLC 

MidPoint Food & Ag Fund, LP 
 MidPoint
Food & Ag Co-Investment Fund, LP 
 Kansas Bioscience Authority 

 EXHIBIT D 

SERIES A-1 PREFERRED HOLDERS 
 RaQualia Pharma Inc. 

 EXHIBIT E 
 COMMON HOLDERS 
 David K. Rosen 
 MPM BioVentures V, L.P. 
 MPM Asset Management Investors BV5 LLC 

Steven St. Peter 
 Louis Mawhinney 

Linda Rhodes 
 Bill Zollers 

Lesley Rausch-Derra 
 Michele Gallucci

 Rose Ann Potter 
 Jim Branch

 Julia Stephanus 

 EXHIBIT F 

INSTRUMENT OF ACCESSION 
 The undersigned,                     , as a condition precedent to becoming the owner or holder of
record of                     (            ) shares of
            stock of Aratana Therapeutics, Inc., a Delaware corporation (the “Company”), hereby agrees to become a
“                    Holder” under that certain Second Amended and Restated Stockholders’ Agreement, dated as of December 28,
2012 (the “Stockholders’ Agreement”), by and among the Company and the parties named therein. This Instrument of Accession shall take effect and shall become an integral part of, and the undersigned shall become a party
to and bound by, the Stockholders’ Agreement immediately upon execution and delivery to the Company of this Instrument. 

IN WITNESS WHEREOF, this INSTRUMENT OF ACCESSION has been duly executed by or on behalf of the undersigned, as a sealed instrument under
the laws of the State of Delaware, as of the date below written. 
  

			
	Signature:
	
	  

		
	(Print Name)	 	  

 

			
	
	Address:
	
	  

	
	  

		
	Date:	 	  

	
	Accepted:
	
	ARATANA THERAPEUTICS, INC.
		
	By:	 	  

		 	Name:
		 	Title:
		
	Date:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00216-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00216-of-00352.parquet"}]]